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ABSTRACT  
   
Schizophrenia is considered a multifactorial disorder with complex genetic variants in 
response to environmental stimuli. However, the specific genetic contribution to schizophrenia 
risk is largely unknown. The transcription factor early growth response gene 3 (EGR3) can be 
activated rapidly after stimuli and thus may translate environmental stimuli into gene changes that 
influence schizophrenia risk. However, the downstream genes that may be regulated by EGR3 
are not clear. While the 5-Hydroxytryptamine receptor 2A (5HT2AR) - encoding gene Htr2a has 
been implicated in the etiology of schizophrenia, the mechanisms by which Htr2a influences 
susceptibility to this illness are poorly understood. We previously found that in addition to 
schizophrenia-like abnormalities, Egr3 -/- mice have approximately 70% deduction of 5HT2AR 
level in the prefrontal cortex, which underlines their resistant to the sedating effect of clozapine. 
These findings indicate that the two schizophrenia candidate genes are in the same biological 
pathway that integrates multiple components resulting in schizophrenia. This dissertation is aimed 
to identify the mechanisms by which Egr3 regulates the expression of Htr2a in response to 
environmental stimuli like stress. 
To determine if Egr3 alters Htr2a transcription under stress, I examined messenger 
ribonucleic acid (mRNA) levels of these two genes in wildtype (WT) and Egr3 -/- mice after 6hrs 
of sleep deprivation (SD). I found both genes are increased in WT mice after SD compared with 
controls. In addition, Egr3 is required for Htr2a induction because SD fails to induce Htr2a 
expression in Egr3 -/- mice. Next, I performed chromatin immunoprecipitation (ChIP) to determine 
if EGR3 binds to Htr2a promoter in vivo. I found a significant increase of EGR3 binding to Htr2a 
distal promoter 2hrs after seizure. To determine the functionality of this binding, I co-transfected 
the CMV- EGR3 vector or CMV- vector alone with the Htr2a distal promoter reporter clone. I 
found overexpression of EGR3 activates the Htr2a distal promoter-driven luciferase gene. 
Although the ChIP assay shows no direct binding of EGR3 to Htr2a proximal promoter, I found 
EGR3 overexpression activates Htr2a proximal promoter-driven luciferase gene. These findings 
suggest that EGR3 regulates Htr2a probably through both direct and indirect ways. 
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1 
CHAPTER 1 
 
INTRODUCTION 
Significance 
Schizophrenia is a disabling disease that affects all major areas of life. Twin studies show 
concordance rates of approximately 50% in monozygotic twins, which is higher than dizygotic 
(17%) twins, and that schizophrenia has a heritability of about 80% (Cardno & Gottesman, 2000). 
This indicates that schizophrenia is not a completely genetic disease. Other factors, such as 
environmental stressors, may interact with genes and contribute to this disease. Better 
understanding of environmental factors may improve our ability to identify the schizophrenia 
susceptibility genes. 
For the past 15 years, my thesis mentor has been investigating the hypothesis that 
immediate early genes (IEGs) are positioned to account for the dual genetic and environmental 
influences on risk for schizophrenia and other psychiatric illnesses. These genes are rapidly 
activated in the brain in response to environmental stimuli, such as stress. The early growth 
response gene3 (EGR3) is an IEG which is expressed extensively in the central nervous system 
and plays important roles in synaptic plasticity, neuronal development, learning and memory (Vol, 
Beckmann, & Wilce, 1997). Thus, dysfunction of EGR3 during development may result in 
pathology that gives rise to the symptoms of schizophrenia.  
Studies have demonstrated that EGR3 is associated with schizophrenia in several 
populations and expressed at reduced levels in postmortem patients’ brains (Huentelman et al., 
2015; S. H. Kim et al., 2010; Tabarés-Seisdedos & Rubenstein, 2009; Yamada et al., 2007b; 
Zhang et al., 2012). EGR3 was recently identified as the central gene in a network of transcription 
factors and miroRNAs implicated in schizophrenia susceptibility (Guo, Sun, Jia, & Zhao, 2010). 
Moreover, Egr3 -/- mice display behavioral abnormalities seen in mouse models of schizophrenia, 
which are reversed by treatment with either haloperidol or clozapine (Gallitano-Mendel, Wozniak, 
Pehek, & Milbrandt, 2008). In addition, our Egr3 -/- mice are resistant to the sedating effect of 
clozapine. This parallels the increased tolerance of schizophrenia patients to antipsychotic effects 
(Cutler, 2001). The EGR3 transcription factor, encoded by EGR3, contains a zinc finger DNA-
2 
binding domain. Thus, identification of the downstream targets regulated by EGR3 will help us 
better understanding the regulatory mechanisms that integrate multiple genetic and 
environmental influences on schizophrenia risk.  
Recently, 5HT2A receptor antagonists have received more attention because they 
improve schizophrenia symptoms with high efficiency, and fewer side effects, compared with 
typical antipsychotics (Iqbal, Asnis, Wetzler, Kay, & van Praag, 1991). Although numerous 
studies have shown that the 5HT2AR-encoding gene Htr2a plays an important role in 
schizophrenia, the influence of environment on Htr2a gene expression, and how this might affect 
schizophrenia risk, remains unknown. We previously found that, in addition to schizophrenia-like 
behavioral abnormalities (Gallitano-Mendel et al., 2007), Egr3-/- mice have a nearly 70% 
decrease in prefrontal cortical 5HT2ARs. This underlies their resistance to sedation by clozapine, 
a phenomenon that parallels the increased tolerance of schizophrenia patients to antipsychotic 
side effects (Williams et al., 2012). These findings indicate that the two schizophrenia candidate 
genes function in the same biological pathway that integrates multiple components implicated in 
schizophrenia. This dissertation is aimed at identifying the potential mechanisms by which the 
immediate early gene Egr3 regulates expression of Htr2a. We accomplished this aim by 
examining the expression levels of genes and proteins and detecting gene regulation 
mechanisms using in vivo and in vitro methods. 
 
Epidemiology of Schizophrenia 
Schizophrenia affects more than 21 million people worldwide according to the current 
report from world health organization (WHO), and approximately 1.2% of Americans have the 
disorder (Nemade & Dombeck, 2009). Concerning prevalence, the median lifetime prevalence 
estimates for persons were 4.0 per 1,000 and for lifetime risk were 7.2 per 1,000 (John, Saha, 
Chant, & Welham, 2008). Concerning sex differences in the incidence of schizophrenia, evidence 
from a meta-analysis shows that the male: female rate ratio is 1.4 (Aleman, Kahn, & Selten, 
2003). However, two recent high-quality prevalence studies confirmed the lack of sex difference 
in lifetime prevalence of schizophrenia, which suggests the sex difference identified in the 
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incidence rates is not reflected in prevalence estimates (Aleman et al., 2003; John et al., 2008). 
Future research is needed to explain such a paradox. In addition, migrant status is strongly 
associated with both an increased incidence and an increased prevalence of schizophrenia. 
Epidemiologic studies examining factors such as social stressors (Selten, Cantor-graae, & Ae, 
2005) and lack of nutrition (Aleman et al., 2003) reveal those factors that are related to 
race/ethnicity play more important role in schizophrenia risk than the migration per se. 
The incidence of schizophrenia has been found to be higher in urban areas than in rural 
regions (Pedersn & Mortensen, 2006). The factors underlying this remain unclear. However, 
environmental pollutants and stress related to overcrowding have been proposed as contributors 
(Cantor-Graae, 2007). Interestingly, Northern latitudes are also associated with the prevalence of 
schizophrenia, but only in males (Saha, Chant, Welham, & McGrath, 2006). It has been shown 
that low prenatal vitamin D levels influence schizophrenia risk (J. McGrath, 1999). Low levels of 
vitamin D are prevalent during winter months and at higher latitudes. Thus, people from high 
latitudes are expected to have a higher incidence of schizophrenia. Frequently, a decrease in 
social, occupational, and interpersonal functioning precedes the onset of overt symptoms of the 
disorder. The “prodrome” that leads to full-blown schizophrenia varies by geographic location, 
with acute onset of the illness has been observed in 70-80% of patients in India and Nigeria, in 
contrast to only approximately 50% of cases in the United States and Europe (Jablensky et al., 
1992).  
The outcome of schizophrenia in developed countries is worse than in developing 
countries, which suggests environment plays a crucial role in schizophrenia risk. It has been 
reported that cases with full remission after a single episode is 3% and 54% in the USA and India, 
respectively. In addition, the percentage of cases with continuous psychotic illness is 2% in 
Nigeria and 33% in Japan (Jablensky et al., 1992). The mechanism underlying this phenomenon 
has not been identified.  One possible explanation is that people in developing counties might be 
more tolerant of illness, and individuals with the illness may receive greater support by family 
attitudes and extended family networks (Jablensky et al., 1992). Studies suggest a reduction in 
the incidence of schizophrenia over time, probably through approaches such as prevention of 
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obstetric complications, while prevalence estimates have remained stable (John et al., 2008). 
Still, cost caused by schizophrenia worldwide represents about 1% of the global burden of all the 
diseases that were estimated in 1990. This number is expected to rise to 1.25% by 2020 
according to the global health estimates of WHO (Murray & Lopez, 1996). In the United States, it 
has been shown that the economic impact of schizophrenia is close to that of diabetes. However, 
considering the potential gains by reducing morbidity and mortality through treatment, higher 
indirect costs are needed for schizophrenia than for diabetes (Barbato, 1998).  Therefore, 
schizophrenia is very costly for both families and society. 
 
Etiology of schizophrenia - genetic and environmental factors 
Over decades, researchers have made a great advance to uncover schizophrenia 
susceptibility genes. The recent genome-wide association studies on 36,989 cases and 113,075 
controls have identified 128 independent associations spanning 108 schizophrenia-associated 
genetic loci (Ripke et al., 2014), 83 of which are newly determined. More than 80% of these loci 
are in or near known gene regions, among which includes genes that involved in encoding 
calcium channels subunits, glutamatergic/dopaminergic/serotoninergic transmission and synaptic 
plasticity. In additions, these associations converge upon genes that are expressed in certain 
tissues/cells instead of randomly distributed across genes of all classes and function. Compared 
to other organs, the risk variants are found more enriched in the brain, particularly in the cortex 
and the striatum. Moreover, they reported single nucleotide polymorphisms (SNPs) on 
chromosome 6, where the major histocompatibility complex (MHC) genes are located, and this 
finding suggest etiological relevance of immune genes and inflammatory pathways with 
schizophrenia. However, examination on gene located at these 108 loci found only six immune 
candidates (DPP4 , HSPD1 , EGR1 , CLU , ESAM , NFATC3 ) which act on both the immune 
system and the brain (Pouget et al., 2016). This suggests that the immune system involves in a 
completely different way compared with autoimmune diseases.  
As discussed above, genetic factors are clearly involved the etiology of schizophrenia, 
but the environment is also crucial to develop the illness. It was proposed that environmental risk 
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factors interact with genetic factors during early life stage in which the formation of the nervous 
system causing abnormalities, and thus leading to psychosis later in life. The early life 
environmental risk factors that have been identified include obstetric complications, prenatal and 
postnatal infection, and others for brain development (Dean & Murray, 2005). Several studies 
found that vitamin D deficiency during pregnancy (J. J. McGrath, Burne, Féron, MacKay-Sim, & 
Eyles, 2010), childhood abuse, season of birth (Mortensen et al., 1999), or adolescent cannabis 
exposure (Malone, Hill, & Rubino, 2010) show strong effects on schizophrenia risk. Moreover, an 
individual’s experience of prenatal or perinatal adverse events increases their risk for 
schizophrenia compared with healthy subjects (M. Cannon, Jones, & Murray, 2002). In addition, 
schizophrenic individuals also display progressive minor physical and cognitive abnormalities 
(Waddington, Torrey, Crow, & Hirsch, 1991). In addition, early developmental delays and 
abnormalities in motor activities and speech, and in social and cognitive development, are 
identified in schizophrenic children in British cohort studies (Jones, Rodgers, Murray, & Marmot, 
1994). These findings suggest that schizophrenia patients probably already have subtle 
abnormalities in brain function very early in life. Environmental factors interact with genetic factors 
and shape individual risk to mental disorders. It has been found that fetal hypoxia reduces gray 
matter (GM) and increases cerebrospinal fluid (CSF) volume in schizophrenia patients compared 
with control subjects (T. Cannon et al., 1993).  
Moreover, environmental risk factors acting later in life are also seen as potential 
etiological factors. Later life risk factors especially drug abuse has been show associated with 
increased risk of psychosis. Studies from Swedish (Andreasson S, Allebeck P, Engstrom A, 
1987) and Dunedin (Arseneault et al., 2002) both reported an elevated relative risk for 
schizophrenia amongst drug users compared to nonusers. In addition, cannabis users who are 15 
years old or later are four times more likely to be diagnosed with schizophrenia (Arseneault et al., 
2002). These findings are consistent with another three large-scale longitudinal investigations in 
Israel (Weiser, Knobler, Noy, & Kaplan, 2002), New Zealand (Fergusson, Horwood, & Swain-
Campbell, 2003), and the Netherlands (J van Os et al., 2002) which all demonstrate a link 
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between cannabis use and later psychosis. Dopamine sensitization may be the reason that 
repeated exposure to drugs of abuse can lead to psychosis (Kapur, 2003).  
Social adversity and stressful life events are thought to be another environmental factor 
that increases risk for psychosis. Stressful life events such as limited access to health care, lack 
of social support, and unemployment are found play a role in schizophrenia susceptibility 
(Sharpley, Hutchinson, McKenzie, & Murray, 2001). In addition, the role of marital status in 
schizophrenia risk is also remarkable. Unmarried individuals are four times likely to develop 
schizophrenia in comparison with their married counterparts (Agerbo, Byrne, Eaton, & Mortensen, 
2004). This finding suggests that marriage and other close interpersonal relationships could act 
as a protective factor for schizophrenia. 
Although both genetic and environmental factors are associated with schizophrenia risk, 
the two risk factors are unlikely to do so in an unrelated manner. Instead, it is proposed that 
environmental risk factors act on a complex set of schizophrenia candidate genes, and the 
interplay between genetic and environmental factors probably determine an individual’s risk for 
schizophrenia. Epigenetic modification is an example of gene-environment interdependence 
which impact gene expressions. Methylome-wide association analysis (MWAS) finds promoter 
methylation is significantly associated with altered gene transcription and thus contribute to 
abnormalities in neurotransmitter systems and neurodevelopment in patients with schizophrenia 
(Y. Li et al., 2015). In addition, human gene-environment interaction studies have emphasized the 
role of integrating genetic risks with environmental factors that leads to diseases (Jim Van Os et 
al., 2014).  
 
Symptoms of schizophrenia 
Since no biological marker has been identified yet, diagnosis of schizophrenia relies on 
mental status examination by clinic interview, and observation of behaviors. There are two major 
current classification systems, ICD-10 and DSM-IV (Barbato, 1998). The two criteria are 
overlapped in some extent but also remain differences. However, the latest version, DSM-V, is 
probably better suited for utilization (American Psychiatric Association, 2013) because it attempts 
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to combine research findings and various diagnostic practices allow understanding the 
neuropathology of the disease. However, different approach to the diagnosis of schizophrenia 
requires considering the boundaries between schizophrenia and other psychotic disorders are not 
clearly defined, so early diagnosis is difficult. No single symptom is specific to schizophrenia, so 
clusters of symptoms need to be considered. In clinical settings, the most observed symptoms 
are (Barbato, 1998): 
A. Delusions: these are false beliefs that are not based in reality, for example, patients may 
suffer from false beliefs of being harmed or harassed. Delusions occur in most people 
with schizophrenia. 
B.  Hallucinations: sensory perceptions in the absence of external stimuli. Hallucinations can 
be in any senses, but auditory hallucinations, especially voices, are classic in 
schizophrenia. 
C. Thought disorder: usually disorganized speech, such as loosening of associations, that 
leads to impaired effective communications. 
D.  Disturbances in motor behavior: such as assuming inappropriate or bizarre positions, or 
complete lack of response. 
E. Negative symptoms: patients may have reduced, or lack of, ability to function normally, 
such as disabilities in work, interpersonal relations, or self-care markedly below the level 
previously accomplished. 
 
Treatment of schizophrenia 
Base on the binding affinity to dopamine receptors and serotonin 2A receptors, 
antipsychotics are separated into three categories (Mailman & Murthy, 2010): 1) typical or 
traditional/conventional antipsychotics that have high dopamine (D2 receptor) antagonism; 2) 
atypical antipsychotics that have high 5-HT2A antagonism; 3) third generation of antipsychotics 
that demonstrate partial D2 agonism and partial 5-HT2A antagonism. 
There are three major brain dopamine pathways: the mesolimbic and meso-cortical 
systems, the nigrostriatal and the tuberoinfundibular (hypothalamic) system (Ungerstedt, 1971). 
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The common action of conventional antipsychotic drugs is they all block dopamine D2 receptors 
mesolimbic and nigrostriatal brain areas (Barbato, 1998). Their effect on psychotic symptoms is 
mediated thorough their action in the mesolimbic system. However, in the nigrostriatal pathway, 
they disrupt basal ganglia functioning and result in extra pyramidal symptoms (EPS), such as 
tardive dyskinesia, a common side effect of conventional antipsychotics. Haloperidol and 
fluphenazine are the most common conventional antipsychotics that can cause EPS (Note, 
2009). In addition, it is evident that these dopamine D2 receptors antagonists are more efficient in 
treating positive symptoms compared with negative symptoms (Patel, Cherian, Gohil, & Atkinson, 
2014). For instance, haloperidol, one of the widely used typical antipsychotics, is effective in 
attenuating the positive symptoms that are associated with acute episodes (Kane, 1989). Studies 
show that 60-65% of D2 receptors must be occupied to decrease the positive symptoms of the 
illness. However, over 77% of D2 blockade rate is associated with EPS (Nyberg, Eriksson, 
Oxenstierna, Halldin, & Farde, 1999). Based on this, methods for determining the lowest effective 
dose are recommended in practice.  
Atypical (also referred to as “second generation) antipsychotics have higher binding 
affinity for 5-HT2ARs than D2 receptors and they act predominantly on mesolimbic neurons with 
little effect on nigrostriatal neurons (Barbato, 1998). The mechanism of action of these 
medications implies an effect on psychotic symptoms with a less extrapyramidal side effect. 
However, they are more likely to have metabolic side effects such as weight gain and diabetes 
mellitus and thus lead to cardiovascular diseases (Raedler, 2010). Atypical antipsychotics are 
more effective in treating negative symptoms compared with typical antipsychotics. This effect 
probably due to the blockade of both 5-HT2A and D2 receptors, resulting in increased level of 
dopamine in the prefrontal cortex where dopaminergic receptors are found to be hypoactive in 
schizophrenia patients (Patel et al., 2014).  
As the atypical antipsychotic, clozapine has been found effective on positive symptoms 
and it can improve psychotic symptoms in schizophrenia patients who are resistant to 
conventional antipsychotics (Buchanan, 1995). However, patients treated with clozapine may 
develop agranulocytosis which can be fatal if not detected. So, patients must have their white 
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blood cell count monitored weekly for the first 18 weeks, and then every two weeks as long as 
they undergo clozapine treatment (Kar, Barreto, & Chandavarkar, 2016).  
Aripiprazole, as the third generation of antipsychotic, was approved in 2002 
(https://www.accessdata.fda.gov). Unlike the typical and atypical antipsychotics, aripiprazole is a 
D2 receptor partial agonist and has partial 5-HT1A receptors agonist activity and 5-HT2A receptors 
antagonist activity (Bandelow & Meier, 2003; Lieberman, 2004). So, in the situation of low 
endogenous dopamine levels, aripiprazole functions as a D2 receptor agonist. On the other hand, 
when endogenous dopamine levels are high, aripiprazole may compete with endogenous 
dopamine and cause partial antagonism offering clinical benefit (Shirley & Perry, 2014). With 
these properties, aripiprazole can moderate dopaminergic hyperactivity in the mesolimbic system 
and compensate dopaminergic hypo-activity in the meso-cortical system (Bandelow & Meier, 
2003; Bowles & Levin, 2003). In addition, the antagonist activity at 5-HT2A receptors may improve 
negative symptoms and cognition deficits, and the function of partial 5-HT1A receptors agonists 
may mediate anxiolytic and anti-depressant effects (Bandelow & Meier, 2003; Grunder, Kungel, 
Ebrecht, Gorocs, & Modell, 2006). Thus, aripiprazole could improve all three categories of 
schizophrenia symptoms: positive, negative and cognitive. However, aripiprazole still has some 
side effects include neuroleptic malignant syndrome and a movement disorder known as tardive 
dyskinesia (Shirley & Perry, 2014).  
Although different generations of antipsychotics are generally effective at improving 
psychotic symptoms in schizophrenia, resistance to treatment and side effects are still major 
challenges of successful treatment of the disorder. A valuable animal model is important for 
research of complex psychiatric disorders like schizophrenia. Indeed, many of the animal models 
for schizophrenia have been validated based on their responsiveness to current drugs.  
A new potential resource for screening novel drugs is host cell lines, especially patient-
specific induced pluripotent stem cells (iPSCs). These are able to self-renew and can be 
reprogrammed into any cell type, create new possibilities for drug discovery. It has been reported 
that several iPSCs from schizophrenia patients such as disrupted in schizophrenia 1 (DISC1)-
mutant neurons (Wen et al., 2014), dopaminergic neurons (Nguyen et al., 2013), serotoninergic 
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neurons (Licinio & Wong, 2016), have been created. The ability to model different stages of 
schizophrenia using cultured iPSCs may help to overcome the limitations of animal models and 
provide the potential for personalized diagnosis and treatment. 
 
Animal models of schizophrenia 
Change in locomotor activity is widely used to validate rodent models of schizophrenia 
and provide a functional measurement of antipsychotic response. The proposed locomotor 
activity measures for schizophrenia are based on the dopamine hypothesis. Studies have found 
that drugs that cause psychosis when given at high doses to humans produce locomotor 
hyperactivity when administered to rodents (Ellenbroek & Cools, 1990). Schizophrenia patients 
also exhibit perseverative, or “stereotyped” behaviors. Thus, many studies using animal models 
have focused on perseveration or stereotypy induced by psychostimulants. Another behavior 
measured in schizophrenia animal model is the startle reflex, namely, the pre-pulse inhibition (PPI) 
of startle paradigm. This is based on the clinic observation that schizophrenia patients are unable 
to automatically filter or ‘‘gate’’ irrelevant thoughts and sensory stimuli they received and thus 
lead to cognition disorders (Braff & Geyer, 1990). Numerous studies have observed deficits in the 
habituation of startle responses of schizophrenia patients (Taiminen et al., 2000). Moreover, 
social withdrawal is one of the characteristic negative symptoms of schizophrenia. Social isolation 
animal model has been studied in monkeys and rats. However, considering the cross-species 
differences, particularly language communication in human social activities, it is difficult to directly 
compare social behaviors across species. 
Schizophrenia patients suffer from cognitive deficits, which are the major contributor to 
their impaired social and vocational functioning (Green, 1996). Although some of the atypical 
antipsychotics, and the third generation antipsychotic aripiprazole, may improve cognitive deficits, 
they lack effectiveness for these symptoms in many schizophrenia patients (Keefe, Silva, Perkins, 
& Lieberman, 1999). Thus, a valuable schizophrenia animal model for discovery of novel 
treatments that target cognitive dysfunctions is crucial. However, because of the limited cognitive 
capacity of laboratory animals it is possible to design behavioral paradigms in rodents that can 
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consider as analogous with those measured in human. Currently, most animal cognitive tasks are 
those with working memory such as delayed matching or nonmatching to sample (Kesner, Hunt, 
Williams, & Long, 1996) and discrete trial delayed alternation (Aultman & Moghaddam, 2001).  
Genetic contributions to schizophrenia have been clearly established. The linkage and 
association studies have identified several schizophrenia candidate genes such as Dysbindin 1 
(DTNBP1) (Owen, Williams, & O’Donovan, 2004), neuregulin1 (NRG1) (Pitcher et al., 2011), and 
Disrupted-in-Schizophrenia-1 (DISC1) (Hennah, Thomson, Peltonen, & Porteous, 2006), early 
growth response 3 (EGR3) (Huentelman et al., 2015), 5-Hydroxytryptamine 2A receptor gene 
HTR2A (Sujitha et al., 2014). Conventional mutant mice of some schizophrenia gene are 
generated (Liu et al., 2005; Tourtellotte & Milbrandt, 1998).  However, dysfunction of those genes 
throughout development and postnatal life may contribute to some of the behavior and physiology 
abnormalities. In addition, some conventional mutant mice such as Egr3 -/- mice developmental 
abnormalities preclude the use of some behavior tests. For example, Egr3 -/- mice have scoliosis 
and lack muscle spindles, resulting in motor abnormalities that interfere with their performance in 
tests requiring certain motor skills (Tourtellotte & Milbrandt, 1998). 
Excitingly, conditional and inducible mutant mice of schizophrenia model have been 
generated, e.g. conditional mutant Disc1 mouse model using the Tet-off system (Pletnikov et al., 
2008). The Tet-off system is controlled by the CAMKII promoter with inducible expression of 
mutant Disc1. This inducible system can limit the Disc1 mutation to forebrain regions. In addition, 
mutant Disc1 transgenic mice exhibit spontaneous hyperactivity in the open field and altered 
social interaction, and transgenic female mice show deficient spatial memory (Pletnikov et al., 
2008). Moreover, conditional mutate Egr3 mice express Cre-recombinase regulated by the 
endogenous Egr3 gene locus was also generated. This method enables selective inactivation of 
Egr3 at any time during development in neurons and Schwan cells  (Oliveira Fernandes & 
Tourtellotte, 2015; Quach, Oliveira-Fernandes, Gruner, & Tourtellotte, 2013).  
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Serotonin system and schizophrenia 
Serotonin, or 5-hydroxytryptamine (5-HT), has been implicated in many physiologic or 
behavioral functions. Moreover, most antipsychotics are currently used for schizophrenia are 
thought to act partially through serotoninergic mechanism. One of the reasons that 5-HT is 
involved in so many process could be the molecular diversity and different distribution of the 5-HT 
receptor subtypes that are expressed in many tissues. ln addition, 5-HT cell bodies clustered in 
the brainstem raphe nuclei but have vast projections to influence all regions in the brain. The 
radioligand-binding assays was developed in 1970s and deepen our understanding the subtypes 
of receptors for serotonin (Frazer & Hensler, 1999). Initially, serotonin binding sites that has high 
affinity to the radioligands [
3
H] 5-HT are designated 5-HT1 receptors, while the ones prefer [
3
H] 
spiperone are termed 5-HT2 receptors. Using molecular cloning techniques and in situ 
hybridization and immunohistochemistry, many of the 5-HT receptors are identified and the 
organization, distribution of those receptors has been demonstrated in cellular and subcellular 
levels.  
Generally, there are two categories of serotonin receptors extensively distributing in 
central and peripheral nervous systems (D Hoyer et al., 1994): 1) ligand-gated ion channel 
receptors (LGICs): the 5-HT3Rs. This receptor super-family consists of five subunits, each of 
which possesses four transmembrane segments and a large, extracellular N-terminal region; 2) G 
protein-coupled receptors (GPCRs): all other subtypes of serotonin receptors, except 5-HT3Rs, 
belong to this family. Members of this receptor family all have the highly conserved seven 
transmembrane domains, an intracellular carboxy-terminus and an extracellular amino-terminus 
(Frazer & Hensler, 1999). 
Sustained agonist exposure could induce internalization, desensitization and down-
regulation of receptors. Agonist binding to cell surface receptors leads to activation of the G-
protein-coupled receptor (GPCRs), then the enzyme GPCR kinase (GRK) phosphorylates the 
receptor. Once phosphorylated, GPCRs are desensitized and internalized into endosomes 
through β-arrestin binding. Once internalized, GPCRs may be recycled back to the cell surface or 
be trafficked to lysosomes and degraded (down-regulation) (Smith, Sim-Selley, & Selley, 2010). 
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In addition to GRK promoted phosphorylation event, second messenger-dependent kinases and 
protein kinases C and A are all indicated involving the desensitization of 5-HT1A receptor 
(Raymond, Mukhin, Gettys, & Garnovskaya, 1999). Protein kinase C also mediates 5-
HT2Areceptor desensitization (Roth et al., 1995). Interestingly, 5-HT2Areceptor antagonists such 
as clozapine also can induce receptor to internalize in cultured cortical pyramidal cells and cause 
the receptor redistribution from dendrites to cell bodies (Willins et al., 1999). However, further 
studies are needed to determine whether this novel antagonist property is related to therapeutic 
action in schizophrenia.  
By interacting with G proteins, those receptors are able to modulate the activity of 
different effector systems to produce an excitatory or inhibitory response. Although serotonin can 
activate those receptors, the activation of different receptors can cause distinct signaling 
pathways that influence various biological and neurological processes such as aggression, 
anxiety, appetite, cognition, learning, memory. The serotonin receptors are also the target of a 
variety of pharmaceutical drugs, including many antidepressants, antipsychotics, hallucinogens. 
Thus, further understanding of those receptors will create more opportunities for drug discovery. 
Early growth response genes 
The early growth response genes (EGRs) are immediate early genes (IEGs). Members of 
this family include Egr-1 (also known as NGFI-A, krox-24, krox-24, zif268 and TIS8), Egr2 (alias 
krox-20), Egr-3 (alias pilot), Egr-4 (alias NGFI-C and pAT133). These genes encode neuronal 
activity-inducible transcription factors. They share a highly homologous (90% identical or 
conserved residues) zinc finger DNA- binding domain which recognizes an identical DNA 
response element (Beckmann & Wilce, 1997). The EGR zinc fingers belong to Cys2His2 class. 
This type of zinc fingers adopts a ββα fold and contains the amino acid sequence motif ‘X2-Cys-
X2,4-Cys-X12-His-X3,4,5-His’ where X represents amino acids that are less well conserved. EGR 
proteins typically contain tandem repeats with more than two of zinc fingers comprising the DNA-
binding domain and each tandem domain binding in the major groove of DNA with a 3-bp 
intervals (Pabo, Peisach, & Grant, 2001). All EGRS recognize and bind to the consensus motif 
GCG
G
/TGGGCG, which is commonly referred to as the GSG motif (Christy & Nathans, 1989). 
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Because of the high conserved binding motif among those proteins, it is more likely that EGRs 
bind to DNA in a similar manner. 
As IEGs, EGRs are rapidly and transiently activated in response to a wide range of 
stimuli. Thus, the activation of EGRs can be the biomarker to map the activation of neuronal 
pathways (Bahrami & Drablos, 2016). In addition, EGRs encode zinc finger transcription factors, 
so the induction of EGRs may also activate downstream genetic cascade and determine the 
program of genetic process leading to the long-term effects of the neuronal stimulation. 
The basal expression level of EGRs is generally low. in situ hybridization studies have 
demonstrated basal expression of Egr1 is detected in the mouse cortex where the highest level is 
in layer IV and VI, and in the hippocampus, with the highest in the CA1, lower in CA2-4 and the 
dentate gyrus (Schlingensiepen, Lüno, & Brysch, 1991). In addition, it has been reported that the 
level of mRNA in rat hippocampus for EGR1 is increased and reaches peak levels at 0.5 – 1hr 
after the maximal electroconvulsive seizure (MECS) (K J O’Donovan, Wilkens, & Baraban,1998). 
EGR1 protein levels closely follow its mRNA expression, with highest levels at 0.5 - 1hr and 
returned to basal levels by 4hrs after seizure. These findings suggest that the expression pattern 
of Egr1 mRNA is correspondently with its protein expression. This probably indicates that the 
basal expression of Egr1 is regulated at transcriptional level. Moreover, the spatial expression 
pattern of Egr1 mRNA and protein is also observed in the physiological excitation of the N-
methyl-D-aspartate (NMDA) subtype of glutamate receptors using natural sensory input. In 
addition, the induction of Egr1 mRNA and protein expression can be abolished by NMDA receptor 
antagonist tetrodotoxin (Worley et al., 1991). These findings suggest that Egr1 not only activated 
by artificial stimuli but also play an important role in mediating normal cortical physiology (Worley 
et al., 1991). In addition to NMDARs, kainate/alpha-amino-3-hydroxy-5- methyl-4-
isoxazoleproprionic acid (AMPA) receptor also induce Egr1 expression in the sensorimotor cortex 
and dorsal striatum, and the AMPARs antagonist DNQX can block the Egr1 activation (Wang, 
Daunais, & Mcginty, 1994).  
In situ hybridization has detected Egr2 mRNA in multiple layers of cortex and white 
matter tracts of the corpus callosum. It is report that EGR2 protein is extensively expressed in 
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neurons in central nervous system (CNS) and in glial cells in peripheral nervous system (PNS). In 
addition, Egr2 is necessary for the myelination of Schwann cells in PNS and the disruption of this 
gene leads to defects in but not affect CNS (Topilko et al., 1994). Egr3 has been found in the 
cerebral cortex, hippocampus, dentate gyrus, caudate putamen and amygdala (Yamagata, 
Kaufmann, Lanahan, Barnes, & Andreasson, 1994). Egr4 expression is highest in cortex and 
rarely detectable in the cerebellum (Crosby et al., 1992). In cerebral cortex, both Egr3, and Egr4 
are highly expressed in layer II (Crosby et al., 1992; Yamagata et al., 1994), and IV except Egr2 
mostly in layer II and III (Herdegen et al., 1993).  
 
Regulation of EGR proteins 
EGR proteins in the central nervous system can be induced by excitatory amino acids, 
mostly the glutamate. It has been reported that glutamate, mainly through the NMDA receptors 
and with partial involvement of AMPA receptors, induces Egr1 mRNA expression in primary 
cortical and striatal cultured neurons (Vaccarino, Hayward, Nestler, Duman, & Tallman, 1992). In 
addition, Kainic acid can induce EGR1 protein and mRNA expression in cortical and hippocampal 
neurons both in vivo (Gass, Herdegen, Bravo, & Kiessling, 1993) and in vitro (T. M. Murphy, 
Worley, & Baraban, 1991), probably via L-type voltage-sensitive calcium channel current. Kainic 
acid induced seizure also activates EGR2 (Gass, Herdegen, Bravo, & Kiessling, 1994) and EGR3 
(L. Li, Carter, Gao, Whitehead, & Tourtellotte, 2005a) protein expression in hippocampus. In 
contrast, the inhibitory neurotransmitter γ-amino butyric acid (GABA) also affect EGR1 protein 
expression in hippocampus. Blocking GABAA receptors by pentylenetetrazole induces Egr1 
mRNA levels in hippocampus and neocortex but not in the midbrain, cerebellum, or brain stem 
(Saffen et al., 1988). Egr4 mRNA is also induced by pentylenetetrazole, mostly in the  dentate 
gyrus, but last longer than Egr1 (Crosby et al., 1992). 
Each of the genes that encode EGR1-4 proteins contain a single exon, which means  
means the zinc fingers are all encoded by the same exon. Previous studies suggested that the 
transient signaling after IEG activation was regulated by combination of several mechanisms for 
rapid degradation and inactivation (Bahrami & Drablos, 2016). e.g. Some of the IEG transcripts 
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were degraded by mircoRNAs targeting 3’UTR regions of those transcripts (Arner et al., 2015). 
The IEG proteins particular FOS transcription factor families are usually unstable and are 
degraded by the proteasome without prior ubiquitination (Gomard et al., 2008).   
All the EGR proteins contain an activation and repression domain outside of the zinc 
finger region, except EGR4 which does not contain a region of homology to the EGR1 R1 
repression domain (Crosby et al., 1992). In addition, the EGR protein repressor NGFI-A binding 
protein 1 (NAB1) repress both EGR1 and EGR2 activity by binding to R1 region, but do not inhibit 
EGR3 (Russo, Sevetson, & Milbrandt, 1995). This difference is probably due to the four amino 
acids in the Egr-3 protein sequence which diverge from those in EGR1 and EGR2. A second 
repressor protein, NGFI-A binding protein 2 (NAB2), which also binds the R1 domain of EGR1 
and EGR2 has been identified (Svaren et al., 1998). Interestingly, nerve growth factor (NGF) 
induces NAB2 but not NAB1 in PC12 cells with slightly delayed kinetics compared with EGR1, 
which indicate the cooperation of the two repressors in regulating EGR proteins. Moreover, it has 
been found that NAB1 does not interfere with DNA regulated by EGR1, but rather forms a 
complex with EGR1 that binds to Egr1 binding sites (A. H. Swirnoff et al., 1998). Overall, these 
findings provide a mechanism for the differential regulation of immediate-early transcription 
factors. 
All the zinc fingers are required and sufficient for nuclear translocation of the EGR1 
transcription factor (Matheny, Day, & Milbrandt, 1994). Mutate the cysteine residues which 
coordinate the zinc ion cause cytoplasmic EGR1 staining, which indicates the secondary 
structure of the zinc fingers may also involves in the nuclear targeting process In addition, The 
zinc fingers are also necessary and sufficient for EGR2 and EGR4 nuclear translocation (Vesque 
& Charnay, 1992). There is no evidence about the nuclear translocation of EGR3 to date. 
Considering the high homology of the zinc fingers between EGR3 and other EGRs, the nuclear 
localization domain of EGR3 would be expected to be similar to that of the other EGRs.  
Posttranslational regulation has been observed for EGR1. It has been reported that 
EGR1 proteins are phosphorylated on a serine residue (Lemaire et al., 1990), and this is induced 
by serum treatment in BALB/c3T3 cells (X Cao et al., 1990). The phosphorylation of EGRs could 
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enhance their DNA-binding activity (Xinmin Cao, Mahendran, Guy, & Tan, 1993). However, most 
of the studies are for EGR1. Further investigation is needed for other EGRs. 
 
EGR proteins are induced by physiological stimulation and seizures 
EGRs can be induced by wide range of stimuli. EGR1 protein are activated by tactile 
stimulation of whiskers predominantly in layer IV rat somatosensory cortex (Mack & Mack, 1991). 
EGR1 protein levels are increased in the suprachiasmatic nucleus of Syrian hamsters following 
exposure to a 1hr light pulse after being adapted to the dark (Holford, 2012). Restraint stress for 
only 10 minutes has been shown induced Egr1 mRNA expression in cerebral cortex and this 
induction can be blocked by administration of β-adrenergic receptor antagonist, propranolol 
(Bing, Filer, Miller, & Stone, 1991). However, water maze training is not able to affect the 
expression of Egr1 mRNA in rat brain (Wisden et al., 1990a). 
 Electroconvulsive seizures (ECS) can induce Egr1 mRNA expression in hippocampus 
and neocortex independently of the NMDA receptor but requires sodium channel activation 
(Minatohara, Akiyoshi, & Okuno, 2016). ECS also induces EGR3 protein but this expression is 
delayed compared to that of EGR1. For example, EGR1 protein starts to increase 1hr and highest 
level is 2hrs after seizure while EGR3 reach peak level at 4hrs but last longer (Kevin J. 
O’Donovan, Tourtellotte, Milbrandt, & Baraban, 1999). 
 
Developmental expression of EGR proteins 
Egr1 expression is rarely detectable in the embryonic nervous system (McMahon, 
Champion, McMahon, & Sukhatme, 1990) but increases throughout postnatal development to 
adult levels. In the neocortex, Egr1 starts to increase in the frontal and occipital cortex at PND 14. 
Hippocampal Egr1 expression is low at birth but increases in all subfields of the hippocampus by 
PND14. In addition, Egr1 expression parallels the time of synaptic formation in the developing rat 
brain (Herms, Zurmohle, Schlingensiepen, Brysch, & Schlingensiepen, 1994). Egr2 is expressed 
in the developing mouse hindbrain at embryonic day 9.5. According to the progress of the 
development, Egr2 is also seen in early neural crest cells, neural-crest derived boundary caps (P. 
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Murphy, Davidson, & Hill, 1989). In addition, both of the transcription factors, EGR2 and Hox-2.9, 
are thought to regulating hindbrain segmentation and development. Egr3 expression is detected 
in the caudate putamen, the hippocampus on PND 1 (Yamagata et al., 1994). Yamagata et al. 
also reported Egr3 expression increases in the neocortex and dentate gyrus on PND 5 and 
reaches adult levels by PND 12. Egr3 has not yet been reported in the embryo. The expression of 
Egr4 in brain is similar to Egr1 and only detected postnatally. Egr4 is first detectable in the 
cerebral cortex, midbrain and cerebellum on PND 7. Then increases to adult levels by day 17 
(Crosby et al., 1992).  
 
EGR3 and schizophrenia 
EGR3 is a transcription factor and the EGR3 gene belongs to immediate early genes 
(IEGs) that are expressed in response to neuronal activity (Beckmann & Wilce, 1997). As an 
effector molecule of mitogen activated protein kinase (MAPK) signaling pathways (Gregg & 
Fraizer, 2011; To, Knower, & Clyne, 2013), EGR2 regulate target gene expressions required for 
long-term structural or physiologic synaptic changes associated with learning and memory, 
functions that are impaired in schizophrenia patients. It has been shown that Egr1 and Egr3 
directly regulate the plasticity-associated activity-regulated cytoskeletal-related gene (Arc, also 
known as Arg3.1), a synaptic activity-induced effector molecule that is also required for L-LTP (L. 
Li, Carter, Gao, Whitehead, & Tourtellotte, 2005b). Similarly, another plasticity-associated gene 
encoding the GABA receptor subunit 4 gene, GABRA4 has been shown to be regulated by Egr3 
in response to seizure in mice (D. Roberts et al., 2005). Both ARC and GABA have been shown 
are associate with schizophrenia. Studies showing that reduced GABA transmission in prefrontal 
cortex of postmortem schizophrenia patients’ brains (Tse, Piantadosi, & Floresco, 2015). An ARC 
SNP is also associated with schizophrenia risk (Huentelman et al., 2015). 
While Egr3 −/− mice appear to have normally developed brains, they have profound 
impairments in context and cue-associated learning and memory, and they have profoundly 
impaired short-term and long-term object recognition memory (L. Li et al., 2007). Our previous 
study also found Egr3-/- mice display short-term memory impairment, and abnormal responses to 
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novelty and handling stress (Gallitano-Mendel et al., 2007). Therefore, we believe Egr3 has an 
essential role in learning and memory presumably by regulating genes required for memory 
acquisition, consolidation and/or retrieval. 
In addition to affecting synaptic plasticity and memory, Egr3 plays a role in promoting the 
immune response to pathogens (S. Li et al., 2012). Studies on patients with schizophrenia 
(Drexhage et al., 2010; Padmos et al., 2008) revealed increased EGR3 protein expression, which 
is also correlated to the increased gene expression of important pro-inflammatory cytokines such 
as IL-1B, TNF and IL-6 in monocytes, suggesting the potential role of transcription factor EGR3 in 
the inflammatory state of schizophrenia patient monocytes (Weigelt et al., 2011). Similarly, 
studies on salivary samples of patients with first-episode psychosis demonstrated that reduced 
BDNF mRNA levels are associated with stress and inflammation (Mondelli et al., 2011). These 
findings suggest altered BDNF and EGR3 gene expressions contribute to psychosis are partly 
induced by stress through a biological pathway that may involve increased inflammation. 
In particular, EGR3, which resides at the chromosomal location 8p21.3, was suggested to 
be a potential susceptibility gene in schizophrenia because chromosome 8p is considered as a 
potential hub for developmental neuropsychiatric disorders (Tabarés-Seisdedos & Rubenstein, 
2009; Yamada et al., 2007b). Studies on different populations have reported that genetic variation 
in EGR3 plays an important role in schizophrenia susceptibility (S. H. Kim et al., 2010; Zhang et 
al., 2012). In addition, decreased prefrontal hemodynamic response during a verbal fluency task 
is associated with an EGR3 polymorphism in schizophrenia patients, indicating genetic variation 
in EGR3 may affect prefrontal cortex function (Nishimura et al., 2014). Animal studies also 
support a role for Egr3 in schizophrenia pathogenesis. We have previously reported that Egr3-
deficient (Egr3−/−) mice display locomotor hyperactivity, a phenotype associated with 
schizophrenia (Gainetdinov, Mohn, & Caron, 2001), which is reversed by treatment with either 
haloperidol or clozapine (Gallitano-Mendel et al., 2008). Moreover, EGR3 was recently identified 
as the central gene in a network of transcription factors and miroRNAs implicated in 
schizophrenia susceptibility (Guo et al., 2010).  
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In summary, EGR3 plays an important role in neuron development, synaptic plasticity, 
learning, memory, and in promoting the immune response to pathogens. However, dysfunction of 
EGR3 could affect its downstream target genes and thus may impair signaling transductions 
which are crucial for those functions. Thus, as an IEG, dysfunction in EGR3 can account for both 
genetic and environmental risk factors for schizophrenia. 
 
Aim of the research  
The goal of this project is to determine the potential mechanism by which Egr3 regulates 
Htr2a in response to stimulation. Identification of the mechanism could provide information for the 
proposed regulatory network which integrates genetic and environmental factors influences on 
schizophrenia and could provide future therapeutic targets to diagnose and treat schizophrenia. 
To determine whether Egr3 alters Htr2a transcription under stress, we will examine mRNA level 
of Egr3 and Htr2a in WT and Egr3-/- mice after 6hrs of sleep deprivation and compared with non-
disturbed controls. To determine whether EGR3 regulates Htr2a by directly binding to Htr2a 
promoter, we will perform chromatin immunoprecipitation using cortical tissues from mice 2hrs 
after seizure. To further identify the functionality of EGR3 binding to Htr2a promoter, we will 
measure luciferase signals after co-transfecting an Htr2a promoter -drive luciferase vector with 
CMV-EGR3 vector or CMV-vector alone in cultured neuro2a cells.  
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CHAPTER 2 
EARLY GROWTH RESPONSE 3 (EGR3) IS ESSENTIAL FOR THE SEROTONIN 2A 
RECEPTOR ENCODING GENE (HTR2A) EXPRESSION IN RESPONSE TO STRESS IN 
MOUSE CORTEX 
Abstract            
Studies have shown that the 5-Hydroxytryptamine receptor 2A (5HT2ARs) encoding gene 
- Htr2a is associated with schizophrenia and expressed at reduced levels in postmortem patients’ 
brains. However, how environmental factors like stress affect Htr2a expression and influence 
schizophrenia risk is not clear. Immediate early genes (IEGs) are the first to be expressed in 
response to environment stimuli. The IEG transcription factor early growth response 3 (Egr3) has 
been associate with schizophrenia. We previously reported that Egr3 -/- mice have a 70% 
decrease of 5HT2ARs in prefrontal cortex which underlies their resistance to sedation by 
clozapine. These findings suggest a potential link between the two schizophrenia candidate 
genes, Egr3 and Htr2a. Particularly, it suggests that Egr3, a transcription factor, may regulate 
expression of Htr2a. 
To determine if environmental stimuli, such as stress could alter the expression levels of 
these two schizophrenia candidate genes, we examined messenger ribonucleic acid (mRNA) 
levels of Egr3 and Htr2a in the cortex of sleep deprived wildtype (WT) mice and found a increase 
of both Egr3 and Htr2a after 6hrs of sleep deprivation (SD) compared with controls. Next, to 
determine if Egr3 is required for Htr2a expression under stress, we measured Htr2a mRNA level 
following SD in Egr3 -/- mice. SD fails to induce Htr2a expression in the cortex of the Egr3 -/- 
mice, suggesting the increase of Htr2a is dependent on Egr3. Htr2a has been shown display an 
anteroposterior gradient pattern in cortex. To further identify the specific cortical regions that 
underline these changes, we examined Egr3 and Htr2a mRNA levels in anterior cortex, prefrontal 
cortex (PFC) and posterior cortex of the same animals used for initial quantification in whole 
cortex. We found that Htr2a is only significantly induced in PFC in an Egr3 dependent manner. In 
addition, Egr3 is activated by SD in PFC and posterior cortex but not in anterior cortex. Our 
findings indicate that Egr3 alteres Htr2a transcription in PFC under SD. Moreover, Egr3 and Htr2a 
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has different distribution in the cortex, with Egr3 is activated to a great degree in the posterior 
cortex and Htr2a display an anteroposterior gradient pattern. 
 
Introduction  
Schizophrenia patients have cognitive deficits, and disturbances in perception and 
behavior, that impair their ability to work, interact with family, and fulfill other major life functions. 
Antipsychotics can reduce the symptoms and allow the patient to function better, but these 
treatments do not cure the illness. A better understanding of the molecular mechanisms of 
schizophrenia will not only increase our knowledge but may also lead to better treatment to 
patients suffering from this mental disorder. 
Both genetic and environmental factors play significant roles in the etiology of 
schizophrenia (Moran, Stokes, Marr, Bock, & Desbonnet, 2016). The serotonin 2A receptor - 
encoding gene Htr2a is one of the most studied schizophrenia candidate genes. Several lines of 
evidence suggest a potential role for dysfunction of this receptor in psychotic illness. 1) The 
serotonin 2A receptor agonists such as lysergic acid diethylamide (LSD), can cause 
hallucinations which is one of the characteristic symptoms of schizophrenia; 2) Almost all atypical 
antipsychotic drugs currently used in therapy, have high affinities for 5-HT2A receptors. 3) The 
levels of Htr2a mRNA and 5-HT2A receptors are found decreased in the frontal cortex of 
postmortem brains of schizophrenic patients (Chalovich & Eisenberg, 2005; Hernandez & 
Sokolov, 2000); 3 4) Htr2a polymorphisms (e.g. rs6311 and rs6313) are also associated with 
schizophrenia (Sujitha et al., 2014). 
In addition, environmental factors such as prenatal/postnatal infection, head injury, drug 
abuse, and social adversity have been reported to influence schizophrenia susceptibility (Dean & 
* The Egr3 and Htr2a expression of the right whole right cortex in this chapter have been 
published (Maple et al., 2015). 
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Murray, 2005). It has been found that individual’s prenatal exposure to infection or famine, and 
perinatal adverse events, increases the risk to develop schizophrenia (M. Cannon et al., 2002). 
Social adversity and stressful life events are environmental factor that increase risk of psychosis. 
Factors such as limited access to health care, lack of social support, and unemployment, are 
associated with greater rates of schizophrenia (Sharpley et al., 2001). However, little is known 
about how environment stimuli affect Htr2a gene expression and thus might influence 
schizophrenia risk. 
Immediate early genes (IEGs) are activated rapidly in response to a wide variety of 
environmental stimuli such as stress (Senba & Ueyama, 1997). Early growth response gene 3 
(EGR3), a member of the EGR family of IEGs, resides at the human chromosomal locus 8p21.3. 
Chromosome region 8p is considered as a potential hub for developmental neuropsychiatric 
disorders (Tabarés-Seisdedos & Rubenstein, 2009; Yamada et al., 2007b). Studies in several 
ethnic populations have reported that genetic variation in EGR3 plays an important role in 
schizophrenia susceptibility (Huentelman et al., 2015; S. H. Kim et al., 2010; Yamada et al., 
2007a; Zhang et al., 2012). In addition, decreased prefrontal hemodynamic response during a 
verbal fluency task is associated with an EGR3 polymorphism in schizophrenia patients, 
indicating genetic variation in EGR3 may affect prefrontal cortex function (Nishimura et al., 2014). 
Moreover, EGR3 was recently identified as the central gene in a network of transcription factors 
and micro ribonucleic acids (miroRNAs) implicated in schizophrenia susceptibility (Guo et al., 
2010). In addition, the zinc finger transcription factor EGR3, that is encoded by the Egr3, 
mediates the transcription of various genes underlying neuronal plasticity and development 
(Gallitano-Mendel et al., 2007; L. Li et al., 2005a). Thus, the activation of Egr3 not only reflects 
local neuronal activity in response to various stimuli, but also induces an internal cascade of 
genetic expression that controls neuronal modifications. However, little is known about the genes 
that are regulated by EGR3 and that contribute to schizophrenia. 
Our previous studies using Egr3 -/- mice revealed abnormalities in behavior and synaptic 
plasticity that resemble those associated with schizophrenia (Gallitano-Mendel et al., 2007). In 
addition, Egr3 -/- mice have a nearly 70% decrease of prefrontal cortical 5HT2ARs, which 
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underlies their resistance to sedation by clozapine, a phenomenon that parallels the increased 
tolerance of schizophrenia patients to antipsychotic side effect (Williams et al., 2012). These 
findings suggest that the 5HT2AR-encoding gene Htr2a may be regulated downstream of Egr3. 
Since Egr3 is activated by environmental stimuli, then, if Egr3 regulates Htr2a, we should 
see changes of Htr2a expression in response to stimulation that activates Egr3. To test this 
hypothesis, we first determined whether SD, a physiologic stimulus, which has previously been 
shown to activate Egr3 expression in WT mice (Thompson et al., 2010), could induce Htr2a gene. 
Then, we used qRT-PCR to compare Htr2a mRNA levels in WT and Egr3 -/- mice during normal 
sleep and after SD. To further identified the specific cortical regions where Egr3 could alter the 
Htr2a gene expression after SD, we examined Egr3 and Htr2a levels in dissected cortical brain 
regions (anterior cortex, prefrontal cortex and posterior cortex). 
 
Methods  
Animals 
The Egr3 -/- mice to be used in the study were generated by the deletion of sequences 
that encode the zinc fingers, the DNA-binding domain of the protein (Tourtellotte & Milbrandt, 
1998). The mice were back-crossed to a C57BI/6 background for more than 30 generations. 
Animals were maintained as heterozygote × heterozygote mating pairs. Egr3 -/- and their WT 
littermates were assigned as ‘matched pairs’ at the time of weaning. Male adult littermates were 
used and housed on a 14/10 h light/ dark schedule with ad libitum access to food and water. 
 
Sleep deprivation (SD)  
Animals were single-housed for 5 days prior to the experimental procedure for 
habituation. Animals were assigned to two groups (Fig.1): 6 hrs sleep deprivation (SD) group, 
time - matched controls allowed to sleep in their home cages (control group). SD started at the 
beginning of the light period (8:00 a.m. mountain standard time, MST). Mice were kept awake by 
“gentle handling” as previously described (Maple, Zhao, Elizalde, McBride, & Gallitano, 2015; 
Thompson et al., 2010). Briefly, animals were disturbed by a combination of cage tapping, 
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introduction of novel objects (e.g., balled paper towels), cage rotation, and stroking of vibrissae 
and fur with an artist’s paintbrush (Terao, Steininger, et al., 2003; Thompson et al., 2010). The 
number and type of stimulation events required to keep each animal awake during the SD 
procedure was recorded by the experimenters and was compared between the WT and Egr3 -/- 
mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) 
Animals were sacrificed immediately after SD via isoflurane overdose. The brains were 
removed and the following regions (Fig.2) were immediately dissected: the entire right cortex, the 
left anterior cortex, left prefrontal cortex, and the left posterior cortex. Brain regions were 
determined using the Coronal C57BL/6J Atlas from the Mouse Brain Atlas (Rosen et al, 2000). 
Collected cortical tissues were treated with RNAlater solutions (ThermoFisher Scientific, Waltham, 
MA) for ribonucleic acid (RNA) stabilization and storage. For RNA isolation, the tissue was 
 
Fig.1. Experimental design for sleep-deprivation (SD) and cortical tissue isolation for 
quantitative reverse transcription polymerase chain reaction (qRT-PCR). Mice were 
assigned to two groups: 6 hrs sleep deprivation (SD) group, time-matched controls for the 
SD group (control group). SD started at the beginning of the light period (8:00 a.m.) and 
ended at 2:00 p.m. All control mice with normal sleep were in their home cages during the 
same period as the SD procedure. All sleep deprived mice and their time-matched control 
were sacrificed the same time immediate after SD. Cortical tissues were removed and 
processed for qRT-PCR to measure the Egr3 and Htr2a expression. 
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homogenized in 700ul of TRI reagent (Life Technologies, Carlsbad, CA) in the 2ml tubes (Bertin 
Corp, Rockville, MD) prefilled with ceramic beads (diameter 1.4 mm). The homogenization 
parameters are: (speed 6000 g, cycle duration 30s) for 4 cycles, in a Precellys 24 high-powered 
bead mill homogenizer (Bertin Corp, Rockville, MD). The samples were put on ice for 2 minutes 
between each cycle to prevent RNA degradation. Next, the homogenates were centrifuged at 
12000g, 4°C for 5 min. The supernatant was saved and was separated into aqueous and organic 
phases by adding 70ul per sample bromochloropropane (BCP, Molecular Research Center, Inc. 
Cincinnati, OH). The RNA was precipitated in a MagMAX express magnetic particle processor 
(Applied Biosystems, Foster City, CA) with isopropanol and washed with ethanol. Next, RNA was 
dissolved in nuclease free water and quantified with ND-1000 Spectrophotometer (Thermo 
scientific, Waltham, MA) and further confirmed with Qubit 3.0 Fluorometer (Thermo scientific, 
Waltham, MA). The mRNA was reverse transcribed into cDNA using M-MLV reverse 
transcriptase kit (Life Technologies, Carlsbad, CA). Quantitative RT-PCR was performed using 
FastStart SYBR green master mix (Roche Applied Science, Indianapolis, IN) with the reaction 
volume 20ul per well (10ul SYBR green master mix 2X, 8ul cDNA, 1ul of each forward and 
reverse primers of 10uM stock) in a 7500 Fast real-time PCR machine (Applied Biosystem, 
Foster City, CA). The thermal cycling parameters are: 50 °C for 2 minutes, 95 °C for 10 minutes, 
40 cycles of (95 °C for 15 seconds, 60 °C for 1 minutes). Quantitative RT-PCR primers are 
designed using primer3 (Koressaar & Remm, 2007) and blasted for targeting specific using the 
software primer-BLAST (https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Primer sequences are 
ordered from Integrated DNA Technologies (IDT, Coralville, IA) with standard desalting 
purification. Primers used for the study are as below: 
Egr3 Forward primer: 5’-CTGGAGGCACTTTCTCCTTG-3’; Egr3 Reverse primer: 5’-
TGGATCAAGGCGATCCTAAC-3’; Htr2a Forward primer: 5’-TCACCATTGCGGGAAACAT-3’; 
Htr2a Reverse primer: 5’-ATCAGCTATGGCAAGTGACAT-3’; Pgk1 Forward primer: 5’-
TGTTAGCGCAAGATTCAGCTA-3’; Pgk1 Reverse primer: 5’-CAGACAAATCCTGATGCAGTA-3’ . 
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Statistical analysis 
For all the qRT-PCR data, the value of cycle threshold (Ct) of gene of interest (Egr3 and 
Htr2a) were normalized to the housekeep gene phosphoglycerate kinase 1 (Pgk1) to be the first 
ΔCt. Relative expression was determined using the comparative 2
-ΔΔCt
 method (Livak & 
Schmittgen, 2001). In addition, the SD project was performed over 4 years (from 2013 to 2016) 
using over more than 5 cohorts of animals. Considering potential environmental variations 
between each study and the rapid activation and degradation feature of Egr3, instead of regular 
comparative 2
-ΔΔCt
 method that combine all first ΔCt of the experiment group and then normalize 
to the combination of all first ΔCt of the control group without considering different cohorts, we 
normalized the first ΔCt of experiment group to the control group of that day to decrease variation 
between each cohort. The gene fold change was calculated by the equation (2
-ΔΔCt
) of SD 
group/(2
-ΔΔCt
) of control group.  
Statistical analysis was performed using Prism 7.0 (GraphPad Software, Inc, La Jolla, 
CA). The amount of the stimulus during SD was analyzed in Graphpad using repeated measures 
two-way ANOVA (RM – two way ANOVA). Unpaired Student’s t-tests with a two-tailed p -value 
were used for conditions in which there were two groups. To determine significant effect in which 
there were two factors, we performed a two-way ANOVA with post-hoc Tukey tests, with gene 
expression levels as the dependent variable, and genotype and experiment conditions as 
independent variables. All values included in the figure legends represent means ± SEM. 
Statistical significance was determined by p < 0.05. 
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a. 
b. 
c. 
Fig. 2. Diagram of cortical regions dissected immediately following SD. Colors (a) indicate 
different cortical regions were collected, right whole cortex (yellow), left anterior cortex (green), 
left prefrontal cortex (pink), left posterior cortex (blue). To collect left anterior cortex, we did a 1
st
 
cut at 2.10mm Bregma showed in (b), then we dissected along the arrow and kept the neocortex 
region above the arrows as left anterior cortex. To remove the prefrontal cortex, we did a 2
nd
 cut 
at 0.14mm Bregma showed in (c), then we dissected along the arrow and kept the neocortex 
region between the arrows as left prefrontal cortex. All the remaining neocortex was collected as 
left posterior cortex. Create figure using the Mouse Brain Atlas as reference (Rosen et al, 2000). 
1
st
 cut 
2
nd
 cut 
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Results 
Wildtype (WT) and Egr3 -/- 
mice require the same 
amount of stimulus during 
SD 
We recorded the 
number of interventions 
required to keep animals 
awake during SD and found 
that the WT and Egr3 -/- mice 
need the same amount to 
stimulus (Fig.3). There is no 
significant interaction between 
time and genotype on the 
number of interventions 
during SD (Fig.3; F4, 88 = 
0.3534, p = 0.8411). However, 
a significant effect of time effect on the number of interventions is observed (Fig.3; F 4, 88 = 5.967, 
p = 0.0003). This indicates that an increased frequency of interventions is required to keep both 
WT and Egr3 -/- mice awake as SD duration increases. There is no significant effect of genotype 
on the amount of stimulus (Fig.3; F 1, 22 = 2.27, p = 0.1461).  
 
SD induces Htr2a expression in the cerebral cortex in an Egr3 - dependent manner 
Our first question is whether SD, a stimulus that activates expression of Egr3 (Thompson 
et al., 2010), could affect Htr2a expression. However, prior to testing this we had to demonstrate 
that we can replicate the previous finding that this stimulus causes and increase in expression of 
Egr3, which had been detected using in situ hybridization to label mRNA. To address this, we first 
examined the levels of Egr3 mRNA using qRT-PCR in the samples from whole cortex after SD in 
 
Fig. 3. WT and Egr3 -/- mice require same amount of 
stimulus during SD. No significant effect of interaction 
between time and genotype is observed (p = 0.8411). A 
significant time effect (p < 0.001) but no significant 
genotype effect on the amount of stimulus (p = 0.1461) is 
detected. Two - way ANOVA with repeat - measurement 
(RM). n = 12. All values included in the figure legends 
represent means ± SEM. 
 
 
30 
WT mice. We found that 6 hours of SD induces a roughly 3.5-fold increase of Egr3 expression in 
compared to non-SD controls (Fig. S4a; t17 = 4.857, p < 0.0001). Next, we measured Htr2a 
mRNA levels from the same samples from WT animals following SD compared with non-SD 
controls. This demonstrated that SD induces a greater than 2-fold increase in Htr2a expression 
compared to non-SD controls. ANOVA revealed a significant genotype by intervention (SD) 
interaction on Htr2a gene expression level (F 1, 29 = 5.948, p =0.0211). There is also a main effect 
of genotype on the Htr2a gene expression (F 1, 29 = 9.752, p =0.0040) but the main effect of 
experiment conditions on Htr2a expression level is not significant (F 1, 29 = 3.33, p = 0.0784). 
Tukey's multiple comparisons test shows that Htr2a mRNA expression level is significantly 
increased in WT mice following SD compared with the non-sleep deprived control group (Fig. 4b; 
p <0.05), but not in the Egr3 -/- mice groups (Fig. 4b; not significant).  
There is also a significant effect of SD on Htr2a mRNA level between the WT and the 
Egr3 -/- mice in the sleep deprived group (Fig. 4b; p <0.01). These findings suggest that the 
immediate early gene Egr3 can be activated by SD. Htr2a gene is also induced by SD in the WT 
b. Htr2a mRNA level after SD a. Egr3 mRNA level after SD 
Fig. 4. In the right cortex, SD induces Htr2a expression and this induction is 
dependent on Egr3. (a) SD induces Egr3 mRNA expression in WT mice. (b) SD increases 
Htr2a mRNA expression in WT mice but not in Egr3 -/- mice. * p < 0.05, ** p < 0.001, *** p < 
0.0001, n = 8-11. All values included in the figure legends represent means ± SEM. 
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mice but this increase is dependent on the Egr3, since the level of Htr2a gene is not changed in 
the Egr3 -/- mice. 
 
 In the anterior cortex, Egr3 and Htr2a expression level does not change following SD  
 
Next, we wanted to identify the specific cortical regions in which SD increases expression 
of Htr2a.  It has been reported that Htr2a has an anterior-posterior gradient of expression in the 
mouse cortex (Mengod, Pompeiano, Martínez-Mir, & Palacios, 1990; Pompeiano, Palacios, & 
Mengod, 1994). We wanted to see if SD was increasing Htr2a levels in regions in which it is 
already expressed, or activating its expression in regions in which there is little to no detectable 
expression at baseline.  
First, we examined the expression of Egr3 and Htr2a in anterior cortex after SD. We 
found there is no significant difference in Egr3 gene expression in the anterior cortex of WT mice 
following SD compared with the non-SD control group (Fig. 5a; t27 = 0.6679; p = 0.5098). In 
addition, there is no significant interaction effect between SD and genotype on Htr2a gene 
a. Egr3 mRNA level after SD b. Htr2a mRNA level after SD 
Fig. 5. In the anterior cortex, there is no significant change of Egr3 and Htr2a 
mRNA expression after SD. (a) SD fails to induce Egr3 mRNA expression in WT mice. 
(b) The level of Htr2a mRNA is not significantly increased following SD. n = 13 -15. All 
values included in the figure legends represent means ± SEM. 
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expression (Fig. 5b; F1, 52 = 0.4406, p = 0.5098). We also did not see the main effect of 
experimental conditions (Fig. 5b; F1, 52 = 3.488, p = 0.0675) as well as the main effect of genotype 
(Fig. 5b; F1, 52 = 0.1129, p = 0.7382) on Htr2 expression. These results suggest that the 
expression of Egr3 and Htr2a is not significantly changed after SD in the anterior cortex.  
 
In the prefrontal cortex, SD induces both Egr3 and Htr2a expression and Egr3 is required 
for Htr2a induction 
In the prefrontal cortex, we found that the Egr3 is significantly increased 2.0-fold in WT 
mice following 6 hours of SD compared with non-sleep deprived controls (Fig.6a; t28 = 2.615, p = 
0.0142). Moreover, there is a significant interaction effect between SD and genotype on the Htr2a 
expression level (Fig.6b; F1, 54 = 6.413, p = 0.143). There is also a main effect of genotype (F 1, 54 
= 11.95, p = 0.0011) and the experiment conditions (F 1, 54 = 5.857, p = 0.0189) on the Htr2a 
expression level. Tukey's multiple comparisons test shows a significantly increase of Htr2a 
mRNA level (1.7-fold) after SD compared with SD controls in WT mice (Fig. 6b; p <0.01) but not 
in the Egr3 -/- mice (Fig. 6b; p = 0.9998). There is also a significant difference of Htr2a 
expression between the WT and the Egr3 -/- mice after SD (Fig. 6b; p <0.001).  
33 
 
 
In the posterior cortex, Egr3, but not Htr2a, is significantly increased following SD 
In the posterior cortex, SD significantly induces Egr3 gene expression with 2.6-fold in the 
WT mice (Fig. 7a; t27 = 3.5; p = 0.0016). However, there is no significant effect of the interaction 
between SD and genotype on the Htr2a mRNA expression level (Fig. 7b; F1, 49 = 0.06356, p = 
0.8020). There is a main effect of experimental conditions on Htr2a expression levels (Fig. 7b; F1, 
49 = 5.976, p = 0.0181) but genotype show no main effect (Fig. 7b; F1, 49 = 0.4822, p = 0.4907). 
These results indicate that SD increased Egr3 expression in the posterior cortex but the Htr2a 
expression is not affected by SD. 
a. Egr3 mRNA level after SD b. Htr2a mRNA level after SD 
Fig. 6. In prefrontal cortex (PFC), sleep deprivation (SD) induces Htr2a mRNA 
expression in a Egr3 dependent manner. (a) SD induces Egr3 mRNA expression in WT 
mice. (b) SD increases Htr2a mRNA in WT mice but not in Egr3 -/- mice. * p < 0.05, ** p < 
0.01, *** p < 0.001, n = 13 -15. All values included in the figure legends represent means ± 
SEM. 
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Discussion 
Schizophrenia is a complex mental disorder influenced by many factors including genetic 
variations at over 100 genomic loci, as well a range of environmental stressors. Numerous 
studies have emphasized the important role of Htr2a dysregulation in schizophrenia. However, 
how environment factors affect Htr2a expression remains unclear. The schizophrenia 
susceptibility gene EGR3, as an IEG transcription factor, is rapidly activated by various stimuli. 
Thus, activation of EGR3 not only reflects local neuronal activity after stimulation but also 
orchestrates a downstream genetic program that presumably modifies neuronal function. Thus, 
identification of the potential targets that are regulated by EGR3 will help us to answer how the 
interaction between genes and environment influence schizophrenia risk.  
Previously, we found a decrease of 5HT2ARs level in prefrontal cortex of Egr3 -/- mice 
(Williams et al., 2012), which suggests Htr2a is potential downstream regulated by Egr3. If Htr2a 
is, indeed, regulated by Egr3, then we would expect to see an alternation of Htr2a expression by 
an environmental stimulus which activates Egr3.  In the present study, we first found that Htr2a 
expression is increased by SD, a stimulus that activates Egr3 (Thompson et al., 2010). Then we 
a. Egr3 mRNA level after SD b. Htr2a mRNA level after SD 
Fig. 7. In posterior cortex, SD induces Egr3 mRNA but not Htr2a mRNA expression. (a) SD 
induces Egr3 gene expression in WT mice. (b) Htr2a mRNA shows no change following SD. ** p < 
0.01. n = 12-15. All values included in the figure legends represent means ± SEM. 
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demonstrated that the increase of Htr2a requires the activation of the immediate early gene Egr3 
because SD fails to induce Htr2a in the Egr3 -/- mice. These findings are exciting because they 
provide evidence for the regulation of Egr3 to its potential downstream target Htr2a. Moreover, 
this is the first report that the level of Htr2a can be rapidly altered, in just six hours, in response to 
a physiologic environmental stimulus. This is particularly important because the 5HT2AR 
mediates the perceptual disturbance caused by hallucinogenic drugs, and the action of 
antipsychotic medications, and is decreased in the brains of schizophrenia patients.  
In the present study, we adopted a ‘gentle-handling’ method, one of the most-frequently 
used SD techniques (L. A. Toth & Bhargava, 2013), which has been applied to rodents and 
causes loss of both non-rapid eye movement sleep (NREMS) and rapid eye movement sleep 
(REMS). In this approach, animals are under continuous observation and disturbed by 
combination of tapping on the cage, providing novel objects, or gentle prodding (e.g., with 
paintbrush). The primary rationale for using this method is that this is one of the few physiologic 
interventions that had been shown to activate expression of Egr3. Besides the gentle-handling 
method, other SD protocols called automated methods (e.g. ‘disk-over-water’ approach) also are 
widely used for animal SD research. In these approaches, the animals are forced to walk to keep 
pace with the disk, otherwise they will be carried into a pool of water (L. A. Toth & Bhargava, 
2013). However, our Egr3 -/- mice display hyper-locomotor activity (Gallitano-Mendel et al., 2007). 
So, the ‘gentle-handling’ was determined to have fewer potentially confounding effects automated 
methods for these animals. Furthermore, our analysis of the amount of stimulus during SD 
reveals that there is no significant difference of intervention intensity between the WT and Egr3 -/- 
mice during SD procedure (Fig.3). However, we do observe a significant time effect on the 
amount of stimulus (Fig.3), which indicates that as the duration of SD increases, the increased 
intensity of arousal intervention is required to keep the mice awake.    
   Stress, such as sleep deprivation is able to rapidly activate the expression of immediate 
early genes (IEGs) in the brain, and labeling of IEGs has enabled the visualization of activated 
neurocircuitry after stress (Senba & Ueyama, 1997; Terao, Greco, Davis, Heller, & Kilduff, 2003). 
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In order to determine if we could induce Egr3 after 6hrs of SD, we measured the Egr3 mRNA 
level in samples of whole cortex using qRT-PCR. We found that there is a significant increase of 
Egr3 mRNA after 6hrs of SD compared with the non-sleep deprived WT control group (Fig.4a). It 
has previously been reported that 6hrs of SD significantly activates the immediate early growth 
gene Egr3 (Terao, Greco, et al., 2003; Thompson et al., 2010) in the mouse cortex using in situ 
hybridization. Our finding of qRT-PCR analysis is consistent with the prior work. 
              Previously we found there is a nearly 70% reduction of 5HT2A receptor in the prefrontal 
cortex of Egr3 -/- mice compared with WT controls (Williams et al., 2012), which suggests that 
Egr3 is required for the expression of Htr2a gene. Next, we want to determine if 6hrs of SD could 
induce the Htr2a expression in mouse, and whether Egr3 is required for the Htr2a gene 
expression in response to the acute physiology stress - SD. We measured the cortical expression 
levels of the Egr3 and Htr2a mRNA after SD. We found that there is a significant increase of 
Htr2a mRNA expression in the right whole cortex of the WT mice following SD compared with the 
non-sleep deprived control group (Fig.4b). However, the induction of Htr2a is not observed in the 
Egr3 -/- mice after SD compared with the control group (Fig.4b). Interestingly, our results in 
animals are supported by a recent study in humans that showed a 24hrs of total SD causes 
significant increases of cerebral serotonin 2A receptor binding in human (Elmenhorst, Kroll, 
Matusch, & Bauer, 2012). In addition, it has been reported that Htr2a has an anterior-posterior 
gradient of expression cortex and Htr2a mRNA level is highest in frontal cortex  (Mengod et al., 
1990; Pompeiano et al., 1994). Next, we wanted to see if SD was increasing Htr2a levels in 
regions in which it is already expressed, or activating its expression in regions in which there is 
little to no detectable expression at baseline. 
                To further identify specific cortical regions in which Htr2a expression is affected by Egr3 
following SD, we removed the left whole cortex from the same mice as the right whole cortex 
study and dissected it into 3 parts (Fig.2): left anterior cortex, left prefrontal cortex and the left 
posterior cortex. We examined both Egr3 and Htrr2a mRNA expression levels in those 3 cortical 
regions using qRT-PCR. Our results indicate that only the prefrontal cortex that displays an 
increase of Htr2a gene expression following SD and is dependent on Egr3 (Fig.6b). There is no 
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significant change of Egr3 and Htr2a in the anterior cortex after SD (Fig.5). In addition, we only 
found the Egr3 induction but not the Htr2a in the posterior cortex of sleep deprived WT mice 
compared with the undisturbed wildtype (WT) littermate controls (Fig.7).   
             Egr3, as an IEG, is the molecular switch to activate targets in response to changes in 
environment, and is expressed at very low level at baseline. However, it can be induced following 
6hrs of SD in the mouse neocortex, particularly in the posterior regions include visual and caudal 
somatosensory cortex using in situ hybridization method (Thompson et al., 2010). Our qRT-PCR 
results showed that the Egr3 mRNA level was increased at 2.0-fold (Fig.6a) and 2.6-fold (Fig.7a) 
in the prefrontal cortex and the posterior cortex respectively, which are greater than the 1.2-fold 
(Fig.5a) of Egr3 mRNA in the anterior cortex. These data suggested that the Egr3 gene was 
activated by 6hrs of SD and the activation mostly was in the posterior cortical area, and this is 
consistent with the prior findings that Egr3 was mostly induced in visual and caudal 
somatosensory cortex (Thompson et al., 2010). 
            Previously, localization studies of the Htr2a gene by in situ hybridization have reported 
that the Htr2a mRNA is expressed in a strong anteroposterior gradient in the rodent cerebral 
cortex, with the highest level is observed in the frontal cortex (Mengod et al., 1990; Pompeiano et 
al., 1994). Furthermore, the study on human show that 24hrs of SD causes significant increases 
of cerebral serotonin 2A receptor binding in the ventrolateral prefrontal cortex (Elmenhorst et al., 
2012). We found that the Htr2a mRNA levels in the anterior and prefrontal cortex of WT mice is 
increased 1.5-fold (Fig.5b) and 1.7-fold (Fig.6b) respectively. In addition, the Htr2a level in the 
posterior cortex was 1.3-fold (Fig.7b). Overall, our qRT-PCR data support the anteroposterior 
gradient distribution of Htr2a mRNA expression in rodent cortex, and the frontal cortex are more 
enriched of Htr2a gene compared with the posterior cortex. Although the cortical region that Egr3 
could alter Htr2a transcription in response to stress was identified, we were unable to determine 
the location in a cellular or subcellular level due to the limitation of qRT-PCR technique. Other 
methods like in situ hybridization would reveal the location or/and organization of the Egr3 and 
Htr2a genes, and immunohistochemistry and autoradiographic assay would allow us to identify 
the distribution and localization of the EGR3 and HTR2A proteins. 
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Both 5HT2AR and its encoding gene HTR2A are found decreased in the frontal cortex of 
postmortem brains of schizophrenic patients (Chalovich & Eisenberg, 2005; Hernandez & 
Sokolov, 2000). In the present study, we show for the first time that a brief intervention, only 6hrs 
of a physiologic environmental change, can drastically alter the level of the Htr2a gene in the 
mouse brain. This is very exciting because SD could be a means to normalize the deficit in 
schizophrenia patients. Although the exact mechanism is not clear, SD has been one of an 
effective treatments for major depressive disorders (Hines, Schmitt, Hines, Moss, & Haydon, 
2013). To our knowledge, SD has not been reported as a schizophrenia treatment to date. 
However, our findings in the animal studies provide potential therapeutic role of SD in this mental 
disorder. SD induced HTR2A expression probably is an adaptation for normal people. However, 
schizophrenia patients lack of HTR2A in response to stimuli because of the deficient of EGR3. 
Our findings are not just limited the laboratory mouse. In fact, similar findings have been reported 
that 24hrs of total SD shows increased binding of cerebral 5HT2ARs in humans using positron 
emission tomography (PET) (Elmenhorst et al., 2012).  
However, people may argue if it is beneficial to increase HTR2A then why many atypical 
antipsychotics are 5HT2AR antagonists? This question brings us to the paradox that 5HT2AR and 
HTR2A are found decreased in postmortem brains of schizophrenic patients (Chalovich & 
Eisenberg, 2005; Hernandez & Sokolov, 2000), whereas most atypical antipsychotics have 
5HT2AR antagonism (Moran et al., 2016) and some of the 5HT2AR agonists can cause 
hallucinations. There is no clear answer for this now. However, it should be noted that the atypical 
antipsychotics clozapine, a 5-HT2ARs antagonist, also acts as an agonist at 5-HT2ARs to counter 
dizocilpine-induced behaviors by activation of Akt/ Protein kinase B (PKB) (Schmid, Streicher, 
Meltzer, & Bohn, 2014). In addition, clozapine also can induce serotonin 2A receptor to internalize 
in cultured cortical pyramidal cells and cause the receptor redistribution from dendrites to cell 
bodies (Willins et al., 1999). So, the antagonist acts on receptors through a very complex manner 
rather than just simply block a receptor. Moreover, all effective antipsychotics currently in use 
bind to D2 receptors. It is also reported that 5-HT2A and D2 receptor antagonists increase 
dopamine release in the prefrontal cortex by via 5-HT1A receptor activation (Ichikawa et al., 2001). 
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Thus, the interaction between dopamine and serotonin systems may determine the efficacy of 
antipsychotics.  
In conclusion, we employed an acute physiology stress, sleep deprivation and 
successfully activate two schizophrenia susceptibility genes, Egr3 and Htr2a. Most importantly, 
we validated that Egr3 is required for the expression of Htr2a in response to stress. Given the 
transcriptional regulation function of EGR3, these results provide potential regulation effect of 
Egr3 on the Htr2a under stressful conditions. 
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CHAPTER 3 
EARLY GROWTH RESPONSE 3 (EGR3) DIRECTLY BINDS TO THE SEROTONIN 2A 
RECEPTOR GENE (HTR2A) PROMOTER AND ACTIVATES GENE EXPRESSION 
 
Abstract 
To date, no gene has been definitively demonstrated to cause schizophrenia. Through its 
action as an immediate early gene transcription factor, EGR3 translates environmental stimuli into 
gene expression changes in the brain that affect numerous cellular and molecular processes that 
are dysfunctional in schizophrenia. However, few of the downstream genes regulated by EGR3 
have been identified. 
While the 5HT2AR- encoding gene Htr2a gene has been implicated in the etiology of 
schizophrenia, the mechanisms by which Htr2a influences susceptibility to this severe mental 
illness are poorly understood. In chapter 2 we describe that sleep deprivation (SD) activates 
Htr2a in an Egr3 dependent manner, particularly in mouse prefrontal cortex (PFC). These findings 
are consistent with our previous finding that the Egr3 -/- mice display approximately 70% of 
decrease in 5HT2AR levels in PFC. We believe that the decrease of Htr2a mRNA and 5HT2AR 
levels in PFC of Egr3 -/- mice underlines the fact that Egr3 -/- mice are resistant to the sedating 
effect of clozapine. Thus, we expected that EGR3, a transcription factor, alters the Htr2a gene 
expression by directly binding to the Htr2a promoter under stress condition. 
In this study, we first identified two putative EGR3 binding sites in the Htr2a promoter by 
bioinformatics analysis. To determine EGR3 protein expression pattern, we performed western 
blot using prefrontal cortical tissues. We found that EGR3 protein levels increased 2 hrs after 
electroconvulsive seizure (ECS). Based on these findings, we performed chromatin 
immunoprecipitation (ChIP) to determine whether EGR3 binds to Htr2a promoter in vivo. We 
found that ECS produces a significant increase in EGR3 binding to the distal EGR consensus 
binding site of the Htr2a promoter. To further determine the functionality of this binding, we tested 
the ability of EGR3 to regulate expression of Htr2a promoter-driven luciferase reporter constructs 
in vitro. Results show that overexpression of EGR3 significantly activates the Htr2a distal 
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promoter- driven luciferase gene. Interestingly, we found that EGR3 also activates expression of 
a luciferase reporter driven by the proximal EGR binding site in the Htr2a promoter, although this 
region was not significantly bound by EGR3 in our ChIP assay.  
 
Introduction 
Over the past decade, researchers have made great advances in identifying 
schizophrenia susceptibility genes. Genome-wide association studies have revealed large 
number of schizophrenia risk genes from 108 schizophrenia-associated genetic loci (Ripke et al., 
2014). Among these are genes that encode calcium channels subunits, and genes involved in 
glutamatergic, dopaminergic, and serotoninergic neural transmission and in synaptic plasticity. 
However, genes cannot fully account for schizophrenia susceptibility. Studies show concordance 
rates of approximately 50% in monozygotic twins, which is higher than dizygotic (17%) twins. 
Research has led to the consensus  that schizophrenia has a heritability of about 80% (Cardno & 
Gottesman, 2000). This indicates that schizophrenia is not a completely genetic disease. Other 
factors such as the environmental events may interact with genes and contribute to this disease. 
Better understanding of the role of environmental factors in schizophrenia risk may help us to 
identify the schizophrenia susceptibility genes. 
The Immediate early genes (IEGs) are rapidly activated within minutes after various 
stimuli, without the need for de novo protein synthesis, thus they are considered as markers for 
neuronal activation (Bahrami & Drablos, 2016). Egr3 is a member of the Early Growth Response 
family of IEGs, which function as transcription factors. Studies on humans and animals support 
the role for Egr3 in schizophrenia pathogenesis (Cheng et al., 2012; Amelia Gallitano-Mendel, 
Wozniak, Pehek, & Milbrandt, 2008; S. H. Kim et al., 2010; Williams et al., 2012; Zhang et al., 
2012). Previously, we found that Egr3 -/- mice display hyper-locomotor phenotype, which has 
been associate with schizophrenia (Gainetdinov et al., 2001). In addition, Egr3 -/- mice are 
resistant to the sedating effect of clozapine which is reversed by treatment with either haloperidol 
or clozapine(Gallitano-Mendel et al., 2008). This parallels the increased tolerance that 
schizophrenia patients have antipsychotic side effects, compared to healthy controls (Cutler, 
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2001). Moreover, a 5HT2AR selective agent MDL11939 can replicate the effect of clozapine in 
Egr3 -/- mice (Williams et al., 2012). This pharmacologic response may be explained by our 
finding that 5HT2AR binding is nearly 70% reduced in the prefrontal cortex of Egr3 -/- mice 
(Williams et al., 2012). This is also supported by findings of studies showing that 5HT2AR-/- mice 
were cataleptic following haloperidol and risperidone treatment, but did not respond to clozapine’s 
locomotor - suppressing effects (McOmish, Lira, Hanks, & Gingrich, 2012) . 
Many studies have shown that the 5HT2AR-encoding gene Htr2a plays an important role 
in schizophrenia. In postmortem studies, it has been reported that expression levels of the 
5HT2AR and the 5HT2AR-encoding gene, Htr2a, are reduced in postmortem schizophrenia 
patients’ brains (Chalovich & Eisenberg, 2005; Hernandez & Sokolov, 2000). Clozapine is one of 
the atypical antipsychotics and is currently one of the most efficacious antipsychotics (McEvoy et 
al, 2006; Meltzer et al, 2003). The most popular explanation for clozapine improving efficacy in 
treating some of the schizophrenia symptoms is the targeting of 5HT2AR. However, even 
numerous studies evident that the dysfunction of Htr2a influence schizophrenia risk, little is 
known about the mechanism by which environment factors alter Htr2a gene expression. Stress, 
such as prenatal/postnatal infection and social adversity, have been reported to influence 
schizophrenia susceptibility (Dean & Murray, 2005). In chapter 2, we employed the method of 
sleep deprivation to expose wild type (WT) and Egr3 -/- mice to a physiologic stress that has 
been shown to induce expression of Egr3 in the WT mouse cortex. We found that 6hrs of SD 
induces both Egr3 and Htr2a expression, particularly in the mouse prefrontal cortex. In addition, 
SD fails to increase Htr2a mRNA level in the Egr3 -/- mice, which indicates Egr3 is required for 
the Htr2a induction in response to stress. Our findings provide further evidence that these two 
schizophrenia candidate genes are in the same biological pathway that integrates genetic and 
environmental risk for schizophrenia 
Based on those findings, we hypothesized that EGR3 directly regulates Htr2a gene 
expression by binding to EGR response elements in the Htr2a promoter. To determine whether 
EGR3 directly binds to Htr2a promoter in vivo, we performed chromatin immunoprecipitation 
(ChIP) using frontal cortical tissues from WT mice 2hrs after electroconvulsive seizure (ECS). To 
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further investigate whether the binding of EGR3 to Htr2a promoter is functional, we co-transfected 
individual Htr2a promoter reporter clones with CMV EGR3 vector or with CMV vector alone. After 
24hrs of transfection in neuro2a cells, we measured luciferase signals which are driven by each 
gene promoter. We hope this study will identify part of the regulation mechanisms between the 
two schizophrenia candidate genes and provide knowledge of how genetic and environmental 
interactions affect schizophrenia risk.  
 
Methods 
Animals 
The Egr3 -/- mice to be used in the study were generated by the deletion of sequences 
that encode the zinc fingers, the DNA-binding domain of the protein (Tourtellotte & Milbrandt, 
1998). The mice were back-crossed to a C57BI/6 background for more than 30 generations. 
Study animals were generated from heterozygote × heterozygote mates. Animals were housed 
on a 14/10 h light/ dark cycle (lights on 8:00 a.m.) with ad libitum access to food and water. All 
animals used for ECS studies were adult wildtype (WT) mice. WT mice from the same litters were 
used as controls. 
 
Electroconvulsive seizure (ECS) 
Ten minutes after placing a drop of proparacaine hydrochloride ophthalmic solution USP, 
0.5% (Akorn) onto each eye, electroconvulsive shock was delivered via silver trans - corneal 
electrodes which previously damped with 0.9% sodium chloride (NaCl, Sigma-Aldrich). Animals 
were restrained by manual scruffing. The pulse generator (ECT Unit 57800 - 001; Ugo Basile, 
Comerio, Italy) delivered a stimulus of 220 - 250HZ (based on weight), 0.9 width square wave 
pulses for a duration of 0.2 seconds at a current of 20mAs (Ramanan, Shen et al. 2005, Ploski, 
Newton et al. 2006). Immediately following the shock, mice displayed tonic-clonic seizures were 
observed hind limb tonic extensions and were placed back in their home cages for recovery.  
Mice were sacrificed and their brains were dissected 2 hrs after ECS. Age matched “no-ECS” 
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control mice from the same litters were sacrificed at the same time of day as the mice 
experiencing seizures.  
 
Western blot to detect the expression pattern of EGR3 protein 2hrs after ECS 
2 hours after ECS, prefrontal cortex was removed and homogenized in the 1% Nonidet 
P-40 lysis buffer containing 0.5% sodium deoxycholate with proteinase inhibitor (1:10,000; 
Sigma-Aldrich, St. Louis, MO) using the Wheaton Tenbroeck style tissue grinder (ThermoFisher 
Scientific, Waltham, MA). Cell debris was pelleted by centrifugation at 17,000 rpm for 5 min, 4 °C. 
The supernatant was saved and protein concentration was quantified using Pierce BCA protein 
assay kit (ThermoFisher Scientific, Waltham, MA). Protein samples were denatured for 5 min, 
100 °C on block heater (VWR, Radnor, PA). 25ug of protein was loaded into homemade 4-8% 
gradient polyacrylamide gels. Following electrophoresis, proteins were transferred to 
nitrocellulose membranes (Bio-rad Laboratories, Hercules, CA) for 1hr using a semi-dry transfer 
apparatus (Bio-rad Laboratories, Hercules, CA) which constantly delivers a voltage of 15 V. Then 
the membranes were blocked for 1hr with 3% (w/v) non-fat dry milk (LabScientific Inc., Highlands, 
NJ). After washing with phosphate buffered saline plus 0.1% of Tween-20 (PBST), the 
membranes were incubated overnight at 4°C with the rabbit anti-EGR3 antibody (1:200, Santa 
Cruz Biotechnology, Dallas, TX) and the mouse anti-beta actin antibody (1:5000, Sigma-Aldrich, 
St. Louis, MO). The next day, membranes were washed with PBST and incubated with 
IRDye800CW secondary antibodies (1:10,000 for EGR3, Li-COR Biosciences, Lincoln, NE) and 
the IRDye680 secondary antibodies (1:20,000 for beta actin, Li-COR Biosciences) dissolved in 3% 
non-fat dry milk for 1hr at room temperature with gentle shaking. After washing for 5 times, each 
time for 5 minutes, the membranes were visualized on an Odyssey instrument (Li-COR 
Biosciences). Protein expression levels were determined as the ratio of EGR3 to the internal 
control beta-actin and were reported as percentage of control group. 
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Bioinformatics analysis to identify putative EGR3 binding sites on the Htr2a gene 
promoter 
To identify potential EGR3 binding sites on the Htr2a gene promoter, first we downloaded 
the promoter sequences which include the region 4kb upstream of the Htr2a transcription start 
site (NM_172812, chr14:74636840-74640839) from genome browser of University of California, 
Santa Cruz (UCSC genome browser, https://genome.ucsc.edu/). Then we scanned 
and identified matches of consensus binding sites for the EGR3 in the 4kb Htr2a promoter 
sequences using the software ‘Find Individual Motif Occurrences’ (FIMO, http://meme-
uite.org/tools/fimo) (Grant, Bailey, & Noble, 2011). The motif occurrences with a p -value less 
than 0.0001 were selected. 
 
Chromatin immunoprecipitation (ChIP) 
ChIP protocol is modified from previously reported (H.-D. Kim et al., 2016). Briefly, 2hrs 
after ECS, frontal cortex was removed and was cut into 1mm pieces using razor blades. Next, we 
crosslinked the protein-DNA complexes by incubating the frontal cortical tissues in 1% 
formaldehyde (Sigma-Aldrich, St. Louis, MO) on a rotator for 12 minutes. Then we quenched the 
formaldehyde with 125 mM glycine (Sigma-Aldrich, St. Louis, MO) for 5 minutes. Next, we 
homogenized samples using a Q125 sonicator (Qsonic, LLC., Newtown, CT) with a power of 
amplitude 40%, sonication duration 7, number of cycles 2. Cool samples on ice between each 
cycle. After that, we sheared chromatin into 200bp-1000bp using a Bioruptor XL (Diagenode Inc., 
Denville, NJ) at 4°C with the high sonication intensity for 30s on/30s off for 35 cycles. Fragment 
size was verified with an Agilent bioanalyzer (Agilent Technologies, Santa Clara, CA). 50ul of 
sheared chromatin were removed as input control with an input fraction 5%. The magnetic beads-
antibody complex was prepared by incubating 7.5ug of the anti-EGR3 antibody (Santa Cruz 
Biotechnology, Dallas, TX) with the magnetic sheep anti-rabbit beads (Invitrogen Corp., Carlsbad, 
CA) at 4°C overnight on a rotator. After washing the bead-antibody complex with 0.5% BSA 
blocking solution, add 70ul of the beads-antibody complex in to each ChIP sample, incubated for 
16hrs at 4°C on a rotator. To control for nonspecific binding, a normal IgG IP was performed in 
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parallel. Next beads were collected by placing sample tubes in a magnetic rack (ThermoFisher 
Scientific, Waltham, MA), then washed with the following buffer: low salt wash buffer (0.1%SDS, 
1% TritonX100, 2mM EDTA, 150mM NaCl, 20mM Tris-HCl), high salt wash buffer (the same as 
low salt wash buffer, except using 200mM NaCl instead), LiCl wash buffer (150mM LiCl, 1%NP40, 
1% NaDOC, 1mM EDTA, 10mM Tris-HCl). Then cross-linked protein and DNA complex were 
reversed at 65°C overnight and RNA were removed by 1hr incubation with 2ul of RNase A 
(Roche Applied Science, Indianapolis, IN) at 37°C. Next proteins were digested with 2ul of 
proteinase K (20 mg/mL, Invitrogen Corp., Carlsbad, CA).  Clean up DNA using a DNA 
purification kit (QIAGEN Inc., Germantown, MD). qPCR was performed using FastStart SYBR 
green master mix (Roche applied science) in a 7500 Fast real-time PCR machine (Applied 
Biosystem, Foster City, CA). The total reaction volume per well was 25ul reaction (2ul DNA, 9.5 
µL nuclease-free water, 12.5 µL SYBR-Green Master Mix 2X, 0.5ul µL of each forward and 
reverse primers with 10uM stock). The thermal cycling parameters are: initial denaturation at 
94°C for 10 minutes, 50 cycles of (denature at 94°C for 20 seconds, anneal and extension at 
60°C for 1 minute). The primers used were as below: 
Arc forward: 5’-TCGCTGCCCAGGACTAGGTA-3’; 
Arc reverse: 5’-TTCACAGCCCCGAGTGACTAA-3’; 
Htr2a proximal forward: 5’-CTTGGATAGAAGTGCTGGATGCT-3’; 
Htr2a proximal reverse: 5’-GGGTACATGGCAGTCATATTTTTAGG-3’; 
Htr2a distal forward: 5’-CTGGGCTCTAAAGGCAACTGA-3’; 
Htr2a distal reverse: 5’-TGCGCACGTGTATACAGAGTAGGT-3’ 
After performing ChIP- qPCR, the relative occupancy (aka. fold enrichment) of the EGR3 
proteins at predicted binding loci of Htr2a putative regulation regions is estimated using the 
following equation 2^(ΔCt MOCK- ΔCt SPECIFIC), where ΔCT MOCK and ΔCT SPECIFIC are 
mean normalized threshold cycles of PCR done in triplicate on DNA samples from MOCK (anti-
IgG antibody) and transcription factor EGR3 immunoprecipitations to the input IPs (Nelson, 
Denisenko, & Bomsztyk, 2006). 
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Promoter reporter vector design 
1, The Htr2a proximal promoter luciferase reporter (Fig. 13) – the dual-reporter system contains a 
Gaussia luciferase gene (GLuc) which is driven by a Htr2a proximal promoter insert which 
corresponds to Htr2a promoter sequence located approximately 1061bp upstream and 200 bp 
downstream of the transcription start site (TSS) of the Htr2a gene. In the same vector, a secreted 
alkaline phosphatase (SEAP) is driven by a cytomegalovirus (CMV) promoter and serves as the 
internal control for signal normalization, and this internal control SEAP exists in all the other 
promoter reporter clones in the present study. This Htr2a proximal promoter luciferase reporter 
contains the EGR3 putative binding site GCGCGGGGGAGGGG (Fig. 9). 
2, The Htr2a distal promoter luciferase reporter (Fig. 12) – this dual luciferase promoter reporter 
clone contains an GLuc gene and is driven by the insert which is -2727bp to -2841bp upstream of 
the Htr2a TSS and this fragment contains the EGR3 putative binding site AGGAGGGGGAGTCT 
(Fig. 9).  
3, The Arc promoter luciferase reporter (Fig. 11) – is a positive control for the illuminometer and 
the functionality of our CMV-Egr3 vector. We used the Arc promoter reporter clone containing an 
insert which is 1049bp upstream and 200bp downstream of the TSS of the Arc gene. This Arc 
promoter luciferase reporter contains the EGR3 binding site ‘GCCGCCCACGGGCC’ (Fig. 9) 
which was confirmed previously (L. Li et al., 2005a). 
4, The non-promoter luciferase reporter – as a negative control would allow us to detect the basic 
activity of the dual-reporter vector. This luciferase reporter contains an insert which is a non-
promoter sequence (TGCAGATATCCTCGCCC). 
All the promoter clones were generated by Genecopeia (Genecopeia Inc., Rockville, MD). 
Promoter reporter plasmid growth 
We transformed 100 ng of each promoter reporter vector into 50 ul of GCI-5a competent 
cells (Genecopeia Inc., Rockville, MD). After incubation on ice for 30 minutes, we performed heat-
shock on a block heater at 42 °C for 42 seconds, and then put on ice for 5 minutes. After that, 
750 ul of room temperature super optimal broth with catabolite repression (SOC, ThermoFisher 
Scientific) medium was added to the DNA - competent cell mixtures. Incubated the mixture at 
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37°C for 1 h with shaking at 225 rpm. Next, plated 10 ul and 100 ul of mixture on Lennox Luria-
Bertani broth agar (LB, ThermoFisher Scientific) plates containing 50 ug/ml kanamycin 
(ThermoFisher Scientific). Incubated the plates at 37°C, overnight. The next day, picked 5 clones 
and grew in 5 ml of Miller’s LB broth medium (ThermoFisher Scientific) containing 50ug/ml 
kanamycin. After overnight growth, plasmid DNA was purified and was sent for sequencing. The 
sequencing primers for all vectors used: forward: 5’-AGTTACTTAAGCTCGGGCCC-3’; reverse: 
5’-TTGTTCTCGGTGGGCTTGGC-3’. This pairs of primers targeted the linker sequence between 
the promoters and the GLuc genes. 
To validated the Htr2a proximal and distal promoter clones, we also used primer3 
(Koressaar & Remm, 2007) to design sequencing primers specific to the Htr2a proximal promoter 
clone: forward: 5’-CTTGGATAGAAGTGCTGGATGCT-3’; reverse: 5’-
GGGTACATGGCAGTCATATTTTTAGG-3’. Sequencing primers specific to the Htr2a distal 
promoter clone: forward: 5’-TGACCTGTTCGTTGCAACAAA-3’; reverse: 5’-
GGCTGTCAGTGACCTCCTTA-3’. 
 
CMV-EGR3 vector, CMV-vector sub-cloning and plasmids growth 
The CMV-EGR3 vector is obtained from Dr. Jeffrey Milbrandt lab (Washington University). 
150 ng of CMV-EGR3 vector was added into 50ul of Dh5alpha competent cells (New England 
Biolabs, Ipswich, MA), incubated on ice for 30 minutes. Next, we performed heat-shock of the 
DNA-competent cell mixture at 42°C for 45 seconds and put on ice for 2 minutes. After adding 
450 ul of room temperature Miller’s LB broth media (ThermoFisher scientific), the mixture was 
incubated at 37°C for 1 h with shaking at 225 rpm. Then plated 10 ul and 100 ul of mixture on 
Lennox LB agar plates which contains 100 ug/ml of ampicillin (ThermoFisher Scientific). Incubate 
the plates overnight at 37°C. The next day, we picked 5 clones and grew in 5 ml of Miller’s LB 
media (ThermoFisher Scientific) containing 100 ug/ml ampicillin (ThermoFisher Scientific) with 
shaking at 180rpm overnight. Then DNA was purified from each LB growth and was digested by 
the restriction enzyme BglII and BamHI (ThermoFisher Scientific) at 37°C for 2 hrs. The clones 
contain the Egr3 insertion were selected for a maximal prep (QIAGEN).   
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To generate the CMV vector, 2 ug of CMV-Egr3 vector was digested by the restriction 
enzyme BglII and BamHI (ThermoFisher Scientific) at 37°C, overnight. After confirming the 
digested DNA that Egr3 has already been deleted by enzyme digestion on a 0.8% agarose gel, 
the CMV vector fragment was cut from the gel and was purified using a DNA gel purification kit 
(QIAGEN). Then the purified CMV vector DNA was ligated using T4 DNA ligase reaction (New 
England Biolabs). The ligation was performed with incubation at 16°C for 2 hrs and then heat- 
inactivated at 65°C for 10 minutes. Next, 1 ul of ligation mixture was transformed into 50 ul of 
DH5alpha competent cells (New England Biolabs). Transformation was performed the same as 
the CMV-EGR3 vector above. 
 
Cell culture and lipofectamine transfection 
Neuro2a cells (mouse neuroblastoma cells; ATCC, Manassas, VA) were maintained in 
Dulbecco's Modified Eagle Medium (DMEM, Gibco,Thermo Fisher Scientific) which contains 10% 
Fetal Bovine Serum (FBS, Gibco) and 1% Penicillin-Streptomycin (PS, Gibco), at 37°C, under a 
humidified atmosphere of 5% carbon dioxide (CO2) : 95% air. Seeded cells into 6-well plate 
(Corning Inc., Corning, NY) with 2 ml of cell culture medium and waited to be 70-90% confluent at 
the time for transfection. 3 hrs ahead of transfection, completed removed original culture medium 
and add 3ml of fresh medium for each well. 1.5 ug of CMV-Egr3 vector or CMV vector was co-
transfected with 1 ug of each promoter reporter vector per well using lipofectamine 3000 reagent 
(ThermoFisher Scientific). Transfection was performed with 3.75 ul of Lipofectamine 3000 
reagent, 5 ul of P3000 reagent and total of 250 ul of Opti-MEM per well. After transfection, cells 
were incubated at 37°C with 5% CO2 : 95% air until further processing. 
Three separate transfections were performed and each transfection was repeated in 
triplicate. 
 
Luciferase signal measurement 
24 hrs after transfection, 0.2 ml of medium from each cell culture was collected and 
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placed at room temperature. The duo luciferase activities were measured using the secrete-pair 
dual luminescence assay kit (Genecopoeia). Each sample was run in duplicate. 
To detect the Gaussia luciferase (GLuc) signal, first diluted the 10X Gaussia luciferase 
stable buffer (GLuc-S) with distilled water to make 1X GLuc-S (1:10). Second, prepared the GLuc 
assay working solution by diluting the Gaussia luciferase substrate with the 1X GLuc-S buffer 
(1:10) and incubated at room temperature for 25 minutes, avoid light. Next, mixed 100 ul of GLuc 
assay working solution with 10 ul of cell culture medium for each well. The mixture was incubated 
at room temperature for 1 minute, avoid light. Then read the signal using a Tecan Safire2 
instrument (Tecan Group Ltd., Morrisville, NC). 
To measure the Secreted Alkaline Phosphatase (SEAP) level, first aliquoted 50 μl of 
each culture medium and heated at 65°C for 15 min, and then placed on ice. Next, prepared 1X 
SEAP buffer by dilute the 10X SEAP buffer with distilled water (1:10). Then prepared the SEAP 
assay working solution by diluting the SEAP substrate with 1X SEAP assay working solution 
(1:10) and incubate at room temperature for 10 minutes, protected from light. After that, 100 ul of 
SEAP assay working solution was mixed with 10 ul of each heated medium sample. Incubated 
the mixture at room temperature for 10 minutes, avoid light. Then read the signal using the Tecan 
Safire2 instrument (Tecan Group Ltd.). 
For all measurements, the GLuc value was first normalized to the intern control SEAP 
luciferase value (GLuc / SEAP ratio) and then to the non-promoter luciferase reporter.  
 
Western blot to measure the EGR3 protein level 24hrs after transfection 
After collecting the cell culture medium for luciferase measurement, we discarded the 
remaining medium in each well. Then the cells were washed 2 times with cold 1X PBS 300 ul per 
well and were lysed with 300 ul per well of 1% Nonidet P-40 lysis buffer containing proteinase 
inhibitor (1:10,000; Sigma-Aldrich). Samples were further homogenized using a Q125 sonicator 
(Qsonica) with a power of amplitude 40%, 1 time for 5 seconds on ice. Then protein concentration 
was quantified using Nanodrop 1000 spectrophotometer (Thermo Scientific). Next, protein 
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samples were denatured and 25ug of proteins for each sample were loaded on gels. Western blot 
was performed as the same as those described in western blot for ECS protein samples above.  
 
Statistical analysis, 
Statistical analysis was performed using Prism 7.0 (GraphPad). Unpaired Student’s t 
tests with a two-tailed p-value were used for conditions in which there were two groups. All values 
included in the figure legends represent means ± SEM. Statistical significances were determined 
by p < 0.05. 
 
Results  
EGR3 protein expression level is significantly increased 2hrs post electroconvulsive 
stimulus  
 Egr3, as an IEG, is the molecular switch to activate targets in response to changes in 
environment, and is expressed at very low level at baseline. However, ChIP-qPCR, a method to 
investigate the interaction between proteins and DNA in the cell, includes many steps such as 
sonication of chromatin, selectively immunoprecipitated protein-DNA complex using an 
appropriate protein-specific antibody and use purified genomic DNA as template for qPCR. Thus, 
first we need to maximize the EGR3 protein levels in animal tissues for performing ChIP. To 
determine the expression timeline of EGR3 protein in the prefrontal cortex, we performed ECS on 
two separate animal cohorts. Protein samples were isolated and were quantified using the 
western blot, we found that 2hrs post ECS, the EGR3 protein level is significantly increased 
compared with the No ECS control group (Fig.1; t10 = 2.28, p <0.05). Those results suggested 
that 2hrs post ECS induced robust activation of EGR3 protein expression in mouse prefrontal 
cortex. 
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Bioinformatics analysis identified two putative EGR3 binding sites on the Htr2a gene 
promoter 
As one of the EGR family transcription factors, EGR3 contains a highly-conserved DNA-
binding domain composed of three zinc-finger motifs. In addition, it has been reported that EGR3 
directly binds to its downstream target gene promoters and regulate the expression of those 
genes  (L. Li et al., 2005a; Mittelstadt & Ashwell, 1998; Salotti, Sakchaisri, Tourtellotte, & Johnson, 
2015). To investigate whether EGR3 could directly bind to the Htr2a promoter and thus might be 
able to activate it, we searched potential EGR3 binding sites on the Htr2a gene promoter using 
FIMO software (Grant et al., 2011). We found two motif occurrences with a p -value < 0.0001. 
The two putative EGR3 binding sites (site A and B) are indicated in the Fig. 9. 
Fig. 8. EGR3 protein expression is significantly increased in the prefrontal cortex 2hrs 
post electroconvulsive stimulus (ECS) compared with No ECS controls. (a) We performed 
ECS using two separate experiment cohorts. The representative blots were displayed in the 
figure. (b) EGR3 protein level of each sample is normalized to the internal control beta actin, 
and further normalized to the No ECS group. *p <0.05, n = 6 per group. All values included in 
the figure legends represent means ± SEM. 
 
 
a. b. 
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Fig. 9. Diagrams of putative EGR3 binding sites in the mouse Htr2a and Arc 
promoters. (a) Two EGR3 binding sites were located -2777bp (site A, 
AGGAGGGGGAGTC) and -61bp (site B, GCGCGGGGGAGGGG) upstream of the Htr2a 
gene transcription start site. (b) Confirmed EGR3 consensus binding site 
‘GCCGCCCACGGGCC’ which is -37bp upstream of the Arc promoter served as a 
positive control (L. Li et al., 2005b). Black boxes indicate coding sequences (CDS), 
transparent boxes indicate non-coding exons. 
a. 
b. 
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Chromatin immunoprecipitation (ChIP) demonstrates EGR3 directly binds to Htr2a distal 
promoter in vivo 
 
To further determine whether EGR3 directly binds to the Htr2a promoter in vivo, we 
performed ChIP. Previously, our western blot results suggested a significant increase of the 
EGR3 protein expression 2hrs post ECS (Fig.8). Therefore, we used mouse frontal cortical 
tissues which were dissected 2hrs post ECS. Genomic DNA bound to EGR3 was isolated by 
ChIP, and was used as template for a quantitative polymerase chain reaction (qPCR) using 
primers specific to the two putative EGR3 binding sites in the Htr2a promoter (Fig.9a). Primers 
specific to the EGR3 binding site in the Arc promoter were used as positive control (Fig.9b). We 
found there is a 4.8- fold increase of EGR3 protein binds to the Htr2a distal promoter (Fig. 9a, site 
A) 2hrs post ECS compared with that of the No ECS control group (Fig.10; t20 = 2.2117, p < 0.05). 
 
Fig. 10. ChIP-qPCR reveals increased binding of EGR3 to the distal promoter of the Htr2a 
gene in the mouse frontal cortical tissues 2 hrs post ECS. Genomic DNA was purified from 
the ChIP and was used as a template for qPCR. The cycle threshold (CT) value of each gene 
promoter was normalized to that of the input and was further normalized to the CT value of the 
negative control antibody IgG IP. Unpaired student t-tests were used to compare the statistical 
significance between the values of the ChIPs from No ECS group vs 2hrs ECS group for each 
gene. (* p <0.05. n = 11).  
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However, there is no significant difference in EGR3 binding to the Htr2a proximal promoter (Fig. 
9a, site A) between the 2hrs post ECS group and No ECS group (Fig.10; t20 = 1.33073, p = 
0.19825). Our positive control group shows a trend of increase of EGR3 binding to the Arc 
promoter after ECS but the difference is still not significant compared with the No ECS group 
(Fig.10; t20 = 1.89413, p = 0.072762). This is not consistent with previous findings that EGR3 
directly binds to Arc promoter in hippocampus (L. Li et al., 2005a). However, as discussed below, 
we used different brain tissues and only examine the frontal cortical tissues 2hrs after ECS, we 
probably will detect EGR3 binds to Arc promoter if we examine more time points following ECS. 
Overall, the ChIP-qPCR results suggested that EGR3 directly binds to the Htr2a distal promoter 
(Fig. 9a, site A) and thus might be able to activate the gene. 
 
EGR3 activates the Arc proximal promoter 
It has been reported that EGR3 directly binds to Arc promoter and actives Arc (L. Li et al., 
2005a). To validate our dual luciferase reporter assay, first we co-transfected a dual luciferase 
reporter clone (Fig. 11a) containing portion of the Arc promoter (-1049bp / +200bp) with a CMV- 
EGR3 vector or CMV-vector alone. We found there is an approximately 4.88-fold luciferase signal 
increase of the Arc promoter reporter clone when overexpress EGR3 compared with the CMV- 
vector alone (Fig.11b). Our results are consistent with previous findings that EGR3 significantly 
activated Arc promoter - driven luciferase (L. Li et al., 2005a). This finding also suggests that 
CMV- EGR3 vector overexpresses a functional EGR3 protein in cultured neuro2a cell, and our 
transfection method and luciferase assay working in our laboratory. 
 
EGR3 activates the Htr2a distal promoter by directly binding 
Our ChIP-qPCR results suggest that EGR3 binds to the Htr2a distal promoter in the 
mouse frontal cortical tissues 2hrs post ECS (Fig. 10). To examine whether this binding is 
functional in vitro, we co-transfected the CMV-EGR3 vector with the dual luciferase construct 
containing an insert from -2727 bp to -2841bp of the Htr2a promoter (Fig. 12a.) into neuro2a 
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cell. A CMV vector which served as a negative control for the EGR3 overexpression was co-
transfected with the promoter reporter clone.  
 
 We found that 24hrs after transfection there is an approximately 3.9-fold increase in the 
Htr2a distal promoter driven-luciferase signal when EGR3 is overexpressed, relative to the 
expression of the CMV vector alone (Fig. 12b; t4 = 21.17, p < 0.0001). Our ChIP and luciferase 
results suggest that EGR3 directly binds to the Htr2a distal promoter and activates Htr2a. 
 
 
Fig. 11. Arc promoter luciferase activity. Dual luciferase reporter constructs containing 
portion of the Arc promoter (a) - 1049bp upstream and +200bp downstream of the 
transcription start site were significantly activated by EGR3 relative to the CMV expression 
vector alone (b). The GLuc value was normalized to the intern control SEAP luciferase 
value (GLuc/SEAP ratio) and then to the non-promoter luciferase reporter. Student’s t-test, 
**** p <0.0001. n = 3. All values included in the figure legends represent means ± SEM. 
a. 
b. 
57 
 EGR3 activates the Htr2a proximal promoter 
Our ChIP-qPCR results show that there is no significant increase of EGR3 binding to the 
Htr2a proximal promoter in the mouse frontal cortical tissues 2 hrs post ECS (Fig. 10). However, 
we still want to know whether EGR3 could affect Htr2a proximal promoter activity, probably 
through an indirectly way. Thus, we co-transfected a promoter reporter clone containing portion of 
the Htr2a promoter which is 1061bp upstream and 200bp downstream of the Htr2a transcription 
start site (Fig.13a) with CM-EGR3 vector or CMV vector alone.  
Interestingly, we found there is about 4.2-fold increase of the Htr2a proximal promoter 
luciferase signal when overexpress EGR3 protein compared with the CMV vector alone (Fig.13b; 
 
 
Fig. 12. Htr2a distal promoter luciferase activity. Dual luciferase reporter constructs 
containing the Htr2a distal promoter region (a) - 2841bp to -2727bp upstream of the 
transcription start site were significantly activated by EGR3 relative to the CMV expression 
vector alone (b). The GLuc value was normalized to the intern control SEAP luciferase value 
(GLuc/SEAP ratio) and then to the non-promoter luciferase reporter. ****p < 0.0001, n = 3. All 
values included in the figure legends represent means ± SEM. 
a. 
b. 
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t4 = 8.977, p < 0.001). Although our ChIP results indicate that there is no significant increase of 
EGR3 binding to the Htr2a proximal promoter after seizure, the luciferase results suggest the 
overexpression of EGR3 also significantly activates Htr2a proximal promoter. 
 
Western blot to confirm overexpression of EGR3 protein 24hrs after transfection 
Our dual luciferase assay results show a significant luciferase signal increase 24hrs after 
co-transfection of CMV -EGR3 vector with promoter reporter clones of our target genes. To 
further validate that we indeed overexpressed EGR3 by CMV-EGR3 transfection, we performed 
western blot using extracted proteins from cultured neuro2a cells after collecting culture medium 
 
 
Fig.13. Htr2a proximal promoter luciferase activity. Dual luciferase reporter 
constructs containing the Htr2a proximal promoter region (a) - 2841bp upstream and 
+200bp downstream of the transcription start site were significantly activated by EGR3 
relative to the CMV expression vector alone (b). The GLuc value was normalized to the 
intern control SEAP luciferase value (GLuc/SEAP ratio) and then to the non-promoter 
luciferase reporter.  ***p < 0.001. n = 3. All values included in the figure legends 
represent means ± SEM. 
 
a. 
b. 
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for luciferase signal measurement. We found that EGR3 expresses at barely detectable level 
24hrs of after CMV vector transfection (Fig. 14). However, the level of EGR3 protein is enriched 
24hrs after CMV-EGR3 vector transfection (Fig. 14). Overall, these results indicate that we have 
successfully overexpressed EGR3 proteins using CMV-EGR3 vector for our promoter reporter 
luciferase assay studies. Moreover, our luciferase signal is significantly increased due to the 
EGR3 transactivation, and the immediate early gene transcription factor EGR3, expressed at 
rarely detectable level in neuro2a cells at baseline. 
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Fig. 14. The expression of EGR3 proteins 24hrs after co-transfect of CMV- 
EGR3 vector or CMV- vector alone with each promoter reporter clone in 
neuro2a cells. EGR3 expressed at barely detectable level in neuro2a cells 24hrs 
after transfected with CMV vector. The transfection of CMV- EGR3 vector enriched 
EGR3 protein levels in the neuro2a cells. 
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Discussion 
In the present study, we examined the regulations of Htr2a by EGR3 using both in vivo 
and in vitro methods. We hypothesized that EGR3 regulates Htr2a by directly binding to the Htr2a. 
This hypothesis was based on our previous findings that 1) 5HT2A receptors are decreased 
nearly 70% in the prefrontal cortex of Egr3 -/- mice, which underlines their resistance to the 
sedating effect of clozapine (Williams et al., 2012); 2) in Chapter 2 we found that Egr3 is required 
for Htr2a expression in response to SD, which suggests a potential regulatory relationship 
between these two schizophrenia candidate genes; 3) we identified two putative EGR3 binding 
sites on the Htr2a promoter using bioinformatics analysis. To test this hypothesis, we first 
performed ECS to induce tonic-clonic seizures on WT mice to maximize the EGR3 protein 
expression. To capture potentially transient binding of EGR3 to the Htr2a promoters, we 
crosslinked the protein-DNA complex using formaldehyde. By performing ChIP-qPCR, we found 
EGR3 directly binding to Htr2a distal promoter and thus might regulate Htr2a gene in vivo. We 
also confirmed the functionality of this binding in vitro by measuring luciferase activity after co-
transfection with a CMV EGR3 vector which overexpressed EGR3 protein together with a Ht2a 
distal promoter driven luciferase reporter construct.  
Prior studies examining the pattern and timeline of IEG expression have predominantly 
focused on mRNA, using in situ hybridization methodology (Cullinan, Herman, Battaglia, Akil, & 
Watson, 1995; Sukhatme et al., 1988; Wisden et al., 1990b). However, gene expression does not 
always correlate with changes in protein expression. For example, it has been reported that the 
levels of mRNA in rat hippocampus for EGR1 and EGR3 are increased in parallel and reached 
peak levels at 0.5 – 1hr after the maximal electroconvulsive seizure (MECS) (K J O’Donovan et 
al., 1998). EGR1 protein level closely follows its mRNA expression, with levels peaking at 0.5 - 
1hr and returning to basal levels by 4hrs after seizure. In contrast, EGR3 protein levels start to 
rise at 2hrs with the highest level at 4-6hrs after seizure.  
In chapter 2, we found that 6hrs of SD significantly upregulated Egr3 mRNA expression 
in the prefrontal cortex. In that study, we did not examine the expression pattern of EGR3 protein 
in the prefrontal cortex. To address this question, we performed ECS, which have been shown 
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robustly induced Egr3 compared with other stimuli (Vol et al., 1997), and examined EGR3 protein 
levels of prefrontal cortical tissues using western blot. We found there is a significant increase of 
EGR3 protein levels 2hrs after ECS. However, we detected two bands of EGR3 protein both in 
vivo and in vitro (Fig.8 and Fig.14). We used the polyclonal anti-EGR3 antibody from Santa Cruz 
(catalog number sc-191) which is known to identify two bands (43/46KDa). The reason for two 
bands could be the polyclonal antibody is not specific for detecting EGR3 protein because the 
EGRs are high homologues. Particularly, the antigen which used for generating the antibody is C-
terminus of the EGR3 protein. The zinc fingers are in this region and are conserved among EGRs. 
Another possibility is both bands are specific for EGR3 but one band is phosphorylated EGR3 
protein. The posttranslational regulation has been investigated for EGR1. It has been reported 
EGR1 proteins are phosphorylated on a serine residue (Lemaire et al., 1990), and this is induce 
by serum treatment in BALB/c3T3 cells (X Cao et al., 1990). The phosphorylation of EGRs could 
enhance their DNA-binding activity (Xinmin Cao et al., 1993). However, further investigation is 
needed for EGR3 phosphorylation. Overall, these finding is consistent with the prior work that the 
expression of EGR3 protein level rises 2hrs after ECS. In addition, it provided the basis for us to 
perform ChIP assay on brain tissues 2hrs after ECS. 
The Htr2a promoter has been extensively studied and found to contain multiple 
regulatory domains, each contributing to the overall expression pattern. A repressor domain 
located between -2.3kb and -4.2kb of the Htr2a promoter acts as the primary determinant for 
neuronal cell-specific transcription (M Toth, Ding, & Shenk, 1994). Moreover, Toth and colleagues 
also found that Mianserin, one of the noradrenergic and specific serotonergic antidepressants 
(NaSSAs), elicits a decrease in 5HT2A receptor density and this is mediated by a repressor DNA 
domain embedded in the basal promoter. They also found that upstream of the repressor there is 
a domain can reactivate the silenced promoter in some non-neuronal cells such as C6 glioma 
cells (Miklos Toth, 1996).  
Interestingly, the putative EGR3 binding site we have identified 2777bp upstream of the 
Htr2a transcription start site also located in the non-neuronal repressor region of Htr2a promoter. 
For those non-neuronal cells thatdo not express endogenous Htr2a probably contain regulation 
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factors that bind within the repressor regions to inhibit Htr2a transcription. In contrast, the 
neuronal cells might express additional regulators to modify the repressor regions. Some of the 
EGR family members have been reported to serve as a transcriptional repressors in certain cells. 
For example, EGR1 served as a repressor for MEF2 transcription activity in both non-cardiac and 
cardiac cells (Zipfel, Decker, Holst, & Skerka, 1997). EGR4 functions as a repressor and binds to 
IL-2 and c-fos promoter to inhibit the gene expression (Zipfel et al., 1997). However, the role of 
EGR2 and EGR3 as transcriptional repressors has not been determined. The EGR transcription 
factors share a highly homologous zinc finger domain which recognizes an identical DNA 
response element (Vol et al., 1997). So, it would be interesting to see if EGR3 is still able to 
activate Htr2a in non-neuronal cells by directly binding to the Htr2a distal promoter which is 
located in the repressor domain. 
Our studies investigating the proximal EGR3 binding site in the Htr2a promotor revealed 
two results that appeared to be inconsistent. The ChIP qPCR suggests no direct binding of EGR3 
to Htr2a proximal promoter in vivo. However, the in vitro luciferase studies show that EGR3 
overexpression activates the Htr2a proximal promoter- driven luciferase reporter. One possible 
explanation for this paradox is that we are unable to detect the binding in our ChIP assay due to 
the low binding affinity of EGR3 for the Htr2a proximal promoter. It’s possible that the EGR3 
binding site in the Htr2a proximal promoter is shared with another transcription factor specificity 
protein 1 (SP1). Sp1 belongs to the Sp/XKLF (Specificity protein/Krüppel-like factor) family 
transcription factors. The DNA binding domain of Sp1 consists of three contiguous Cys2His2 Zinc 
(Zn) fingers which are very similar with those that of EGRs transcription factors (Vol et al., 1997). 
Both the EGR1 binding motif (GCG
G
/TGGGCG) and SP1 motif (
G
/TGGGCGGGGC) are usually 
present in mammalian (G+C)-rich promoters that lack the TATA and CCAAT box motifs (Huang, 
Fan, Ni, Mercola, & Adamson, 1997).  
It has been reported that SP1 and EGR1 have overlapped binding motif in some gene 
promoters, e.g. murine adenosine deaminase (ADA) and double-sex and Mab-3 related 
transcription factor 1 (Dmrt1) (Ackerman, Minden, Williams, Bobonis, & Yeung, 1991; Lei & 
Heckert, 2002). Moreover, SP1 competes with EGR1 and binds to EGR1 binding motif to activate 
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luciferase gene in cultured Drosophila cells (Kutoh & Schwander, 1993). The two EGR1 binding 
sites in the Htr2a basal promoter overlap with SP1 binding motifs (Garlow & Ciaranello, 1995). 
However, the functionality of this overlap between SP1 and EGR1 in the Htr2a promoter has not 
yet been determined. It would be interesting to determine how the interplay of the two 
transcription factors affects Htr2a gene expression. Nevertheless, all EGR family transcription 
factors contain the same DNA-binding zinc finger domain, and thus recognize the same DNA 
consensus binding sequences. So, it is possible that SP1, or the other EGR family proteins (all of 
which are upregulated in by ECS), competed for the binding site in the Htr2a proximal promoter, 
resulting in lower levels of EGR3 binding that we were unable to pull down in our ChIP study. 
EGR3 activates Arc gene expression by directly binding to the Arc gene promoter (L. Li et 
al., 2005a). We used Arc promoter reporter clone as a positive control for the in vitro luciferase 
and found that EGR3 activates Arc promoter- driven luciferase gene. However, we did not see 
significantly increase of EGR3 binding to Arc promoter 2 hrs post ECS in the ChIP assay, which 
is not consistent with prior work that EGR3 directly binding to Arc promoter (L. Li et al., 2005a). 
We performed ChIP based on the finding that EGR3 proteins significantly increase 2hrs post ECS 
using western blot. However, MECS induced EGR3 levels in mouse hippocampus have been 
shown to rise at 2hrs after seizure and reach peak level at 4-6 hrs (Kevin J. O’Donovan et al., 
1999). Moreover, ECS induced biphasic expression of Arc mRNA in mouse hippocampal CA1 
region, with a first wave 30 minutes after ECS and returned to baseline by 4 - 6 hrs, and a second 
one at 8 hrs post stimuli (Penke, Chagneau, & Laroche, 2011).  In addition, EGR3 was shown to 
be required for Arc protein expression in the dentate gyrus 4 hrs after kainic acid-induced 
seizures in an immunohistochemistry study (L. Li et al., 2005a). Those studies were performed on 
hippocampal tissues. It has not determined whether the expression patterns of Egr3 and Arc in 
the frontal cortex resemble those in the hippocampus. So, it is possible that we would detect that 
EGR3 directly binds to Arc promoter if we perform ChIP-qPCR using frontal cortical tissues from 
several timepoints ranging between 1- 6hrs after ECS. 
 In conclusion, we found that EGR3 alters the Htr2a gene expression by directly binding 
to the Htr2a distal promoter. Excitingly, we also found EGR3 activates Htr2a proximal promoter-
65 
driven luciferase even though the ChIP-qPCR data does not support direct binding between them. 
As we discussed above, the activation of EGR3 to Htr2a proximal promoter probably through 
some intermediates such as c-fos, or through directly binding. However, to further validate 
whether both or either of the putative binding sites are required for the directly regulation of Htr2a 
by EGR3, we still need to mutate the individual EGR3 binding site of the Htr2a promoter using 
site-directed mutagenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
CHAPTER 4 
GENERAL DISCUSSION 
Summary of Major Results 
Both Egr3 and Htr2a are associated with schizophrenia (Huentelman et al., 2015; 
Nishimura et al., 2014; Sujitha et al., 2014; Yamada et al., 2007b). Our previous findings that 
5HT2A receptors are decreased in prefrontal cortex (PFC) of Egr3 -/- mice suggest a potential 
regulatory relationship between these two schizophrenia susceptibility genes (Williams et al., 
2012). The aim of this dissertation is to identify the mechanism by which the immediate early 
gene Egr3 regulates the expression of Htr2a, under basal conditions and in response to stress.  
In chapter 2, we found that 6hrs of sleep deprivation (SD) activates expression of both 
Egr3 and Htr2a, particularly in the prefrontal cortex. These findings are consistent with prior work 
reporting that SD increase the expression of Egr3 (Thompson et al., 2010) in mice and 5HT2AR 
levels in (Elmenhorst et al., 2012) in humans. Furthermore, the increase of Htr2a is dependent on 
Egr3 because SD fails to induce Htr2a in Egr3 -/- mice, which supports our previous findings that 
5HT2AR protein is decreased in the PFC of Egr3 -/- mice (Williams et al., 2012) with findings at 
the mRNA level. Our examination in sub-regions of the cortex revealed that SD activates Egr3 
mostly in posterior cortex (2.6-fold) and Htr2a mostly in PFC (1.7-fold), which indicates that gene 
expression pattern in our study resembles those in prior work (Mengod et al., 1990; Pompeiano et 
al., 1994; Thompson et al., 2010). In addition, even Egr3 -/- mice display a hyper-locomotor 
phenotype (Gallitano-Mendel et al., 2007), but our analysis of the amount of stimulus show that 
WT and Egr3 -/- mice need the same amount of intervention to maintain wakefulness. 
In chapter 3, our chromatin immunoprecipitation (ChIP) show that ECS induces 
significant binding of EGR3 to Htr2a distal, but not proximal, promoter. We further confirmed the 
functionality of EGR3 binding to Htr2a distal by co-transfecting Htr2a distal promoter-driven 
luciferase vector with CMV Egr3 vector or CMV vector alone. Interestingly, even though ChIP 
shows no significant binding of EGR3 to Htr2a proximal promoter, we found that overexpression 
of EGR3 activates the Htr2a proximal promoter-driven luciferase gene. The paradox could be 
explained by 1) EGR3 activates Htr2a proximal promoter through other transcriptional regulators. 
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We believe c-fos is one of the intermediates because Egr3 is required for c-fos expression (Fig.15) 
and the ENCODE project has identified EGR1 binding site in c-fos promoter 
(https://www.encodeproject.org/). In addition, C-FOS heterodimerizes with JUN to form AP-1 and 
activates luciferase gene driven by a Htr2a proximal promoter (Garlow & Ciaranello, 1995); 2) 
SP1 competes with EGR3 and results in low binding affinity of EGR3 binding to Htr2a proximal 
promoter.  
 
Concluding Remarks 
The findings in chapter 2 and 3 provide potential mechanisms by which the immediate 
early gene Egr3 regulates the expression of Htr2a. Numerous studies have emphasized that 
dysregulation of Htr2a is associated with schizophrenia (Gejman, Sanders, & Kendler, 2011; 
Sujitha et al., 2014). However, little is known about how environmental factors affects Htr2a 
expression and influence schizophrenia risk. For years, we have been focusing on the Egr3, a 
IEG that activated rapidly after stimulation. EGR3 has been identified as the central gene in a 
network of transcription factors and miroRNAs implicated in schizophrenia susceptibility (Guo et 
al., 2010). In the present study, we found that Egr3 regulates Htr2a transcription in response to 
stress, and this regulation is by direct binding of EGR3 to a Htr2a distal promoter. Our findings 
suggest that the induction of HTR2A in response to stress likely represents a physiological 
response. These findings suggest the possibility that the reduced levels of 5HT2ARs repeatedly 
identified in schizophrenia patients may result from deficient induction of HTR2A, due to 
insufficient activation of EGR3 protein. Although the increased HTR2A expression may appear 
beneficial, it is rather paradoxical that many antipsychotics block 5-HT2ARs (Meltzer & Huang, 
2008) but 5-HT2ARs agonists such as lysergic acid diethylamide (LSD) are hallucinogens 
(González-Maeso et al., 2003). The paradox is difficult to be deciphered partly because of 
complicated biological context. For instance, the atypical antipsychotics clozapine, a 5-HT2ARs 
antagonist, also acts as an agonist at 5-HT2ARs to counter dizocilpine-induced behaviors by 
activation of Akt/Protein kinase B (PKB) (Schmid et al., 2014).  
68 
 To our knowledge, this is first report that identifies directly regulation mechanisms 
between the two schizophrenia susceptibility genes, EGR3 and HTR2A, under stress conditions. 
In addition, these exciting findings supporting our proposed regulatory network in which 
environmental factors act on a complex set of schizophrenia candidate genes including Htr2a via 
activation of the immediate early gene EGR3, and the interplay between genetic and 
environmental factors probably determine an individual’s risk for schizophrenia. 
 
Potential regulatory networks integrate genetic and environmental influences on 
schizophrenia risk 
Genetic inheritance is one of the factors that contribute to the cause of schizophrenia 
(Cardno & Gottesman, 2000). Environmental stimuli such as stress may interact with a complex 
set of schizophrenia candidate genes and influence the susceptibility to the disease. EGR3 is an 
IEG that activated by various stimuli and is associated with schizophrenia (Huentelman et al., 
2015; S. H. Kim et al., 2010; Mexal et al., 2005; Yamada et al., 2007b; Zhang et al., 2012). 
Numerous studies show that EGR3 is a downstream gene of many schizophrenia risk 
associated proteins. For instance, EGR3 can be induced by N-methyl-D-aspartate (NMDARs). 
Pretreating rats with NMDARs antagonist failed to induce Egr3 mRNA compared with no 
treatment group (Yamagata et al., 1994). Moreover, Hypofunction of the NMDAR pathway 
contributes to etiology of schizophrenia (Olney, Newcomer, & Farber, 1999). EGR3 is also 
regulated by the calcium-responsive protein phosphatase calcineurin (CN) (Mittelstadt & Ashwell, 
1998), which probably is induced by a calcium influx through NMDARs (Sheng & Kim, 2011). 
Human genetic studies show that CN signaling is associated with schizophrenia susceptibility 
(Gerber et al., 2003). Coincidentally, the conditional calcineurin knockout mice exhibit multiple  
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abnormal behaviors such as increased locomotor activity and decreased social interaction 
(Miyakawa et al., 2003) are very similar to our Egr3 -/- mice (Gallitano-Mendel et al., 2007, 2008). 
Another schizophrenia candidate protein brain-derived neurotrophic factor (BDNF) also regulates 
EGR3 via a PKC/MAPK-dependent pathway (Daniel S Roberts, Hu, Lund, Brooks-Kayal, & 
Russek, 2006) and the induced EGR3 thus activates GABRA4 promoter and leads to 
upregulation of GABA(A) receptor alpha4 subunit expression (D.S. Roberts et al., 2005). Egr3 is 
also regulated by the neuregulin1 (NRG1) by stimulating the transcriptional activity of cAMP 
response element binding protein (CREB) and serum response factor (SRF) (Herndon, 
 
Fig 15. Biology pathway that potentially influences schizophrenia risk. EGR3 is 
upstream and downstream of schizophrenia risk associated proteins (red text). The 
dysfunction of EGR3, or its upstream/downstream regulators could induce a cascade of 
genetic expression that controls neuronal modifications and thus influences 
schizophrenia risk.  
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Ankenbruck, Lester, Bailey, & Fromm, 2013). In addition, NRG1 and its receptor ErbB4, a 
receptor tyrosine-protein kinase, participate in cognitive dysfunction in schizophrenia by 
suppressing proto-oncogene tyrosine-protein kinase Src-mediated upregulation of synaptic 
NMDAR function (Pitcher et al., 2011).  
In addition to be downstream of susceptibility genes, EGR3 also directly regulates genes 
that have been associated with schizophrenia. As discussed above, Egr3 stimulates the 
expression of GABRA4 by binding its promoter (D.S. Roberts et al., 2005) and thus upregulates 
of GABA(A) receptor alpha4 subunit expression. Studies showing that reduced GABA 
transmission in prefrontal cortex of postmortem schizophrenia patients’ brains (Tse et al., 2015). 
Moreover, EGR3 directly binds to ARC promoter and activates this gene (L. Li et al., 2005a). ARC 
SNPs is also associated with schizophrenia risk (Huentelman et al., 2015). Our present study 
also shows that EGR3 activates Htr2a by directly binding to Htr2a promoter. Overall, those 
findings led us to propose a regulatory network (Fig. 15) that integrates genetic and 
environmental factors influences on schizophrenia risk. 
 
Limitation of the current study 
In the study, we used the Egr3 -/- mice which are generated by the deletion of sequences 
that encode the zinc fingers, the DNA-binding domain of the protein (Tourtellotte & Milbrandt, 
1998). Although studies on these animals revealed no detectable differences in the distribution 
and density of neurons compared with WT mice (L. Li et al., 2007), it is still unclear the potential 
function of the truncated EGR3. In addition, deleting regions outside the zinc fingers increases 
the DNA-binding activity of EGR proteins such as EGR1 and EGR2 (Carman & Monroe, 1995; 
Vesque & Charnay, 1992). In contrast, intact EGR1 protein displays higher DNA-binding affinity 
compared with the zinc finger domain alone (Vesque & Charnay, 1992). Moreover, the 
sequences outside the zinc finger region of EGR4 are responsible for its faster dissociation rate 
from target DNA relative to other EGR proteins ( a H. Swirnoff & Milbrandt, 1995). However, the 
functions of the sequences outside the zinc finger region of EGR3 are not determined. We cannot 
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exclude the possibility that the truncated EGR3 protein has a dominant inhibitory effect in the 
Egr3 -/- mice which we are unable to detect in the present study. 
It is also possible that other transcription factors, particularly EGRs, may functionally 
compensate for the loss of EGR3. EGRs are highly homologous and bind to the same DNA 
consensus binding motif (Vol et al., 1997). It has been shown that EGR3, rather than EGR1, is 
required for Arc expression in the dentate gyrus following seizure. However, the full induction of 
Arc after novel environment exposure is depend upon both EGR1 and EGR3 (L. Li et al., 2005a; 
Penke et al., 2011). These findings suggest that the Arc expression is controlled by both EGR1 
and EGR3. Thus, it is not determined whether other EGRs are compensating for the lack of 
functional EGR3. In addition, dysfunction of Egr3 throughout development and postnatal life may 
contribute to some of the 
behavior and physiologic 
abnormalities identified in Egr3-/- 
mice. With the Egr3 conditional 
knockout mouse, we would be 
able to selectively inactivate Egr3 
at specific stages of development 
and in selected organs or cell 
types. In addition, we would be 
able to perform specific 
behavioral tests that require 
intact motor skills, which is 
precluded now because the 
muscle spindle morphogenesis is 
impaired and thus leads to 
abnormal proprioception in the 
current Egr3 -/- mice (Tourtellotte & Milbrandt, 1998). 
 
 
Fig. 16.  Egr3-dependent expression of mouse c-fos 
gene. Illumina expression microarray performed on 
mouse hippocampal RNA at baseline (No ECS) versus 
1hr post electroconvulsive stimulation (ECS) showed that 
c-fos mRNA expression is increased in WT but not Egr3 -
/- mice in response to ECS. Two-way ANOVA. ****p 
<0.0001. n = 4. All values included in the figure legends 
represent means ± SEM. 
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Future directions  
Characterize the role of EGR3 in regulating Htr2a proximal promoter 
The ChIP- qPCR suggests no direct binding of EGR3 to Htr2a proximal promoter in vivo. 
However, our in vitro luciferase studies show that EGR3 overexpression activates the Htr2a 
proximal promoter-driven luciferase reporter. One possible explanation for this paradox is that the 
activation of the Htr2a proximal promoter-driven luciferase construct is not through direct binding 
of EGR3, but occurs via other intermediating transcriptional regulators. One intermediate gene 
between EGR3 and Htr2a is c-fos, an IEG which encodes the transcription factor C-FOS. It can 
heterodimerize with the JUN family transcription factors to form the transcription factor complex 
activator protein -1 (AP-1) which binds DNA promoters and enhancer regions of target genes 
(Chiu et al., 1988). We have previously found that Egr3 is required for c-Fos gene expression in 
hippocampal tissues 1hr post electroconvulsive seizuer (ECS) (Fig. 16). Furthermore, the 
ENCODE project has produced genome-wide data for investigating different aspects of genomic 
regulation, including DNA-binding of transcription factors (https://www.encodeproject.org/). The 
ENCODE TFBS ChIP-sequencing analyses demonstrate a EGR1 binding site in the c-fos 
promoter in three cell lines (GM12878, H1-hESC and K562, Lab PI: Richard Myers, Hudson 
Alpha Institute for Biotechnology). The ENCODE TFBS ChIP also identified two C-FOS binding 
sites in the Htr2a promoter (in MCF10A-Er-Src cell line; Lab PI: Kevin Struhl, Harvard Medical 
School). In addition, it has been shown that in cultured neuro2a cells, AP-1 activates luciferase 
promoter reporter clone contains an insert which is 1000bp upstream and 300bp downstream of 
Htr2a transcription start site (Garlow & Ciaranello, 1995). Therefore, it is possible that the 
overexpression of EGR3 induces c-fos expression and results in increased AP-1 directly binding 
to the Htr2a proximal promoter and thus activates the luciferase gene. 
Thus, to determine whether EGR3 regulates Htr2a proximal promoter through the 
intermediate c-fos, it would be necessary to mutate the AP-1 binding motif (5’-TGA
G
/CT
C
/AA-3’) 
(Garlow & Ciaranello, 1995) in the mouse Htr2a proximal promoter. If this mutation could 
decrease or abrogate the Htr2a proximal promoter driven-luciferase activity which is induced by 
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EGR3 expression, then this would provide direct evidence that c-fos is an intermediate 
transcription factor functioning between EGR3 and activation of the Htr2a proximal promoter.  
It has been reported that SP1 and EGR1 have overlapped binding sites on the Htr2a 
proximal promoter (Garlow & Ciaranello, 1995). So, it is possible that SP1 competes with EGR3 
for the overlapping binding motif in Htr2a proximal promoter results in low binding affinity of EGR3 
to Htr2a and thus we did not catch the binding in ChIP. However, EGR3 probably still activates 
the Htr2a promoter by week binding or through interacting with SP1. In this case, the presence of 
SP1 and the role of SP1 need to be determined. Incubate an anti-SP1 specific antibody (Ab) and 
anti-EGR3 Ab with nuclear extracts in the super-shift electrophoretic mobility shift assay (EMSA) 
would allow to us to detect the binding of both transcription factors to the Htr2a proximal promoter. 
However, to confirm the regulation of SP1 and EGR3 by direct binding to the promoter, site-direct 
mutagenesis would be required to mutate their binding motif in in vitro luciferase assays.  
Moreover, three overlapping SP1 and EGR1 binding sites has been found in the 
promoter of tissue factor (TF), a gene involved in blood coagulation, with SP1 binding 
preferentially to site 1 and 3 while site 2 has high affinity to EGR1 (Cui et al., 1996). Sp1 is 
constitutively expressed and mediates basal gene activity by binding to all three sites. EGR1 
binding to site 2 accounts for the strong upregulation of TF in response to phorbol12-myristate 
13-acetate (PMA) or serum stimulation. Thus, the output of the interaction between SP1 and 
EGR3 on certain gene could be dependent on the cellular environment.  
 
How the promoter context of Htr2a affects the actions of EGR3 
In chapter 3, we show that EGR3 activates Htr2a expression by directly binding to the 
Htr2a distal promoter. We also found that EGR3 activates Htr2a proximal promoter-driven 
luciferase gene expression through an unclear mechanism. However, in vitro luciferase reporter 
system which contains the synthetic promoter constructs provides information concerning EGR3 
potential action on the promoter, but does not necessarily provide information about the specific 
contribution of EGR3 and other co-regulators to regulation of the natural, full Htr2a promoter. The 
transcriptional regulation actions of EGRs may be controlled by the promoter context of the target 
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gene. It has been reported that cell types affect the activation or repression action of EGR1 on a 
gene. For example, EGR1 activates the platelet-derived A chain gene in human embryonic kidney 
cell 293 (HEK293) but represses transcription in murine NIH 3T3 fibroblasts (Wilms et al., 1999). 
Thus, the ability of EGR1 to function as an activator or repressor of transcription is cell-type 
specific.  
As discussed in chapter 3, the distal EGR3 binding site is located in the repressor domain 
of Htr2a gene (see also Fig.17). The repressor domain acts as the primary determinant for 
neuronal cell-specific transcription (M Toth et al., 1994). In addition, upstream of the repressor 
there is a domain that can reactivate the silenced promoter in some non-neuronal cells such as 
C6 glioma cells (Miklos Toth, 1996). A potential molecular mechanism for limiting Htr2a 
expression to specific cortical regions is the known repression domain of the Htr2a promoter. I 
would hypothesize that the non-neuronal cells that do not express endogenous Htr2a likely  
express cellular factors that bind to, or modify the structure of, the Htr2a promoter repressor 
domains.  
 
Fig. 17. EGR3 binds to a repressor domain of the mouse Htr2a promoter. A non-
neuronal cell repressor domain exists between -1.2kb and -3.1kb upstream of Htr2a 
transcriptional start site (TSS, +1). The promoter region up to -4kb is sufficient for brain 
specific expression. The EGR3 distal binding site (A, AGGAGGGGGAGTC) is in the 
repressor region while the proximal binding site (B, GCGCGGGGGAGGGG) is in the base 
promoter region.  * Figure is modified from Dr. Miklos Toth’s paper (Miklos Toth, 1996). 
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In addition to EGR1 serving as a repressor for MEF2 transcription activity in both non-
cardiac and cardiac cells (Zipfel et al., 1997), EGR4 also has been found to function as a 
repressor by binding to IL-2 and c-fos promoters to inhibit the gene expression (Zipfel et al., 
1997). However, the role of EGR2 and EGR3 as transcription repressors is not determined. It 
would be interesting to test the transcriptional activity of EGR3 on the Htr2a distal promoter in 
non-neuronal cells. 
Moreover, it has been found that SNPs in the HTR2A promoter could affect EGR3 
binding to this gene in humans. For instance, using bioinformatics analysis, the minor allele for 
rs6311 impacts the alignment of consensus binding site for EGR3 at the rs6311 region of the 
HTR2A gene (Ruble et al., 2016). In the same study, Ruble et al. identified other transcription 
factors that potentially bind at the rs6311 region such as the nuclear factor 1 family (NFIA/B/C). 
However, further analysis and experiments are necessary to test the effect of SNPs in EGR3 on 
binding to the HTR2A promoter. 
 
Are Egr3 -/- mice deficient in serotonergic excitation of callosal/commissural (COM) 
projection neurons in PFC? 
The findings of sleep deprivation (SD) in chapter 2 reveal that Egr3 alters Htr2a 
transcription in the mouse prefrontal cortex (PFC). The PFC is highly interconnected with other 
regions of the brain, including projections to the contralateral cortex and to the pontine nuclei 
(Avesar & Gulledge, 2012; Barbas, Hilgetag, Saha, Dermon, & Suski, 2005). Previous 
electrophysiological studies have shown that 5-HT selectively excites layer 5 pyramidal neurons 
(L5PNs) of callosal/commissural (COM) projection in PFC that innervate the contralateral cortex 
by acting on 5HT2ARs (Avesar & Gulledge, 2012). In contrast, 5-HT elicits inhibition in L5PNs of 
cortico-pontine (CPn) projection, which is mediated by 5HT1ARs. We have found that Egr3 -/- 
mice have approximately 70% reduction of 5HT2ARs in PFC (Williams et al., 2012). In addition, 
this dissertation’s findings suggest Egr3 is required for Htr2a induction after SD because SD 
failed to induce Htr2a in Egr3 -/- mice. These findings lead us to ask the question of whether Egr3 
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-/- mice are deficient in serotonergic excitation of COM projection neurons in PFC due to lack of 
Htr2a? 
To answer this question, we already started collaboration with Dr. Allan Gulledge’s 
laboratory from neuroscience center at Dartmouth College. We performed electrophysiology 
recording using the protocol previously reported (Stephens, Avesar, & Gulledge, 2014). Briefly, 
we first performed stereotaxic injections of fluorescent beads (Retrobeads, Lumafluor Inc.) 
unilaterally into the contralateral medial prefrontal cortex (mPFC) to label COM projections, or into 
the pons to label CPn projections. After surgery, animals were in their home cages over 72 hrs for 
recovery. Electrophysiology recordings were performed in the coronal brain slices (250 μm thick) 
of the mPFC in artificial cerebral spinal fluid (aACSF). 100 μM of 5-HT dissolved in aACSF was 
puffed by a patch pipette placed ∼50 μm from the targeted soma during recording. Based on their 
initial response to 5-HT, neurons are defined as “COM-excited” or “COM-biphasic”. The inhibition 
response to 5-HT was quantified as the duration of cessation of the action potential (AP).  The  
 
excitation response was quantified as the peak increase in AP, relative to the average baseline 
firing frequency. The biphasic response was defined as an inhibition duration which is over 10 
 
Egr3-/- mice
 
 
Egr3-/- mice
n=28  
Fig. 18. 5-HT focal application induces different responses in layer 5 pyramidal neurons 
(L5PNs) of callosal/commissural (COM) projection in Egr3 -/- mice (a) and WT mice (b) with 
Taconic and Jackson laboratory C57BL/6 mice background, respectively. Figure 18b is from 
Avesar & Gulledge study (Avesar & Gulledge, 2012) and is used with permission. 
 
a. b. 
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times the average baseline interspike interval, followed by an increase of AP over 1 Hz. To 
confirm if a specific neuronal response to 5-HT is mediated by 5HT1ARs or 5HT2ARs, antagonists 
for 5HT1ARs (WAY 100635, 30 nM; Sigma–Aldrich) and/or 5HT2ARs (MDL 11939, 500 nM; Tocris 
Bioscience) were applied to some experiments. 
           
To date, we recorded Egr3 -/- mice, with 28 cells of COM projections (n=3 mice) and 33 
cells of CPn projections (n=3 mice). We found 4 different responses to 5-HT in COM L5PNs of 
Egr3 -/- mice (Fig.18a.): 5HT2AR-mediated excitation (39% of L5PNs), 5HT1AR-mediated inhibition 
(25% of L5PNs), biphasic responses in which 5HT2AR-mediated excitation followed 5HT1AR-
mediated inhibition (11%), and no response neurons (25% NR). In contrast, previous studies 
(Avesar & Gulledge, 2012) found that 5-HT induces 58% excitation, 35% biphasic response, and 
7% NR of COM L5PNs in WT mice (Fig.18b). These findings suggest that the decreased 
excitation and increased inhibition in Egr3 -/- mice are due to decreased 5HT2AR level in COM 
L5PNs. Among the 33 cells we recorded in CPn projections in our Egr3 -/- mice, 94% are 
inhibited by 5-HT application, while 3% are excited and 3% are biphasic (Fig.19a). However, 
Avesar & Gulledge (Avesar & Gulledge, 2012) found that CPn L5PNs are 100% inhibited by 5-HT 
 
 
Fig. 19. 5-HT focal application induces different responses in layer 5 pyramidal neurons 
(L5PNs) of cortico-pontine (CPn) projection in Egr3 -/- mice (a) and WT mice (b) with 
Taconic and Jackson laboratory C57BL/6 mice background, respectively. Figure 19b is 
from Avesar & Gulledge study (Avesar & Gulledge, 2012) and is used with permission. 
 
 
a. b. 
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in WT mice (Fig.19b). Since the L5PNs inhibition response is mediated by 5-HT1ARs in CPn 
projection, our findings suggest a decrease of 5-HT1ARs CPn L5PNs in the Egr3 -/- mice. 
However, it should note that our Egr3 -/- mice are from Taconic (C57BL/6NTac), while 
the WT mice from Avesar & Gulledge study are from Jackson Laboratory (C57BL/6J). Even both 
of the mice are C57BL/6, it has been reported that there are genetic and behavior difference 
among the C57BL/6 substrains (Bothe, Bolivar, Vedder, & Geistfeld, 2004; MEKADA et al., 2009; 
Palmer & Mcroberts, 2013). For instance, 12 of 342 simple sequence length polymorphism 
markers (3.5%) were found different between C57BL/6J and C57BL/6NTac mice (Bothe et al., 
2004). Genotyping for single nucleotide polymorphisms (SNPs) loci shows genetic differences 
between C57BL/6J and other C57BL/6 substrains including C57BL/6NTac (MEKADA et al., 2009). 
In addition, the C57BL/6J demonstrates approximately a 2-fold latency to fall off than the 
C57BL/6NTac in the rotarod performance (Bothe et al., 2004). Compared with other C57BL/6 
substrains such as C57BL/6NTac and C57BL/6NCrl (Charles River), C57BL/6J mice also display 
enhanced motor coordination and reduced level of conditional fear (Palmer & Mcroberts, 2013). 
So, we cannot exclude the possibility that the different responses to the 5-HT application of our 
Egr3 -/- mice compared with the WT mice from Avesar & Gulledge study could due to the 
differences among C57BL/6 substrains.  
To answer this question, we started to record WT mice from our lab which has the 
C57BL/6NTac background. So far, we recorded 16 cells of COM projections (n=1 mouse) and 5 
cells of CPn projections (n=1 mouse). Unfortunately, we observed L5PNs of both COM and CPn 
projections in those WT mice from our lab demonstrate the same response to 5-HT as our Egr3 -
/- mice. However, we still cannot make any final conclusion yet because we only recorded one 
WT mouse for COM and CPn projections. More animals are needed to investigate whether Egr3 -
/- mice are deficient in serotonergic excitation of callosal/commissural (COM) projection neurons 
in PFC. 
We also filled target neurons with biocytin when performed electrophysiology recording 
(Figure 20a). Brain slices were fixed with 4% PFA and biocytin-filled neurons were avidin 
conjugated with Alex Fluor 550 (Invitrogen). Then we reconstructed the labeled neurons using 
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Neurolucida neuron tracing software (MBF Bioscience, Williston, VT) (Figure 20b). Sholl analysis 
will be performed on reconstructed neurons to quantify and compare the complexity of dendritic 
arbors between Egr3 -/- and WT. 
 
 
Troubleshooting and alternative strategies 
1, The SD project was performed over 4 years (2013 to 2016) and 5 cohorts of animals were 
included. Considering the feature of Egr3 as an IEG that can be rapidly activated and degraded, I 
employed several strategies to decrease the variation between each study. First, schedule the 
SD experiment on the day when no construction is taking place in the building and fewer people 
are working in the animal colony room. Light and sound are stimuli that activate IEGs. So, control 
animals should not be disturbed more excessively than normal in their home cages. Second, try 
to dissect animals from matched pairs at the same time since Egr3 mRNA degrades very quick. 
Otherwise, different dissecting time can cause gene expression differences within the same 
group. Third, if you have many cohorts, as I did, gene expression from animals which are sleep 
a) 10X b) 
Fig. 20. Representative images of biocytin labeled neurons and neuron tracing. 
(a) Representative images of biocytin labeled layer 5 pyramidal neuron after electrophysiology 
recording in mouse prefrontal cortex. (b) Example of three-dimensional reconstruction of pyramidal 
neuron with the soma (red), basal dendrites (white), apical dendrites (green) using Neurolucida 
neuron tracing software (MBF Bioscience, Williston, VT).  
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deprived should be normalized to the control on the same day. It will be helpful for replication of 
the results. 
2, For the ChIP-qPCR, I combined anterior and prefrontal cortical tissues because mouse 
prefrontal cortex is tiny (around 15mg). The exact amount of tissue needed for ChIP may vary 
depending on protein abundance, antibody affinity etc. and should be determined for each tissue 
type. Many publications and company manuals suggested more that 25mg of tissues for ChIP. 
Our qRT-PCR data of SD project in chapter 2 show Egr3 alters Htr2a expression only in 
prefrontal cortex but not in the anterior cortex. Unfortunately, there is no evidence about how the 
combination of anterior and prefrontal cortex would affect our ChIP results. In future, people in lab 
can combine prefrontal cortical tissues from serval animals of the same group.  
3, Several questions should be considered to optimize experimental conditions for in vitro 
luciferase. 1) Which transfection reagent is appropriate for your cell type? I started with calcium 
phosphate transfection in neuro2a cells but have very low transfection efficiency. Calcium 
phosphate is probably effective in transfecting DNA into non-neuronal cell lines while 
Lipofectamine is more appropriate for neuronal-derived cell lines. 2) How long after transfection 
should we collect cell supernatant medium to check luciferase activities? It is necessary to check 
luciferase signals after transfection at a variety of different time points. This will depend on the 
gene promoter activities. 3) How much plasmid DNA should be transfected into cells? This is 
particularly important for weak gene promoter detection. In chapter 3, we can see that using the 
same amount of DNA, Arc promoter driven luciferase signal is higher than the Htr2a promoter 
driven luciferase signal. Different dilutions of plasmid DNA should be used for optimization of 
transfection for a specific promoter reporter clone. 
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The 5-HT1 receptor family includes 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F 
receptors. They are all Gi/Go-protein coupled proteins which couple negatively to adenylate 
cyclase and lead to membrane depolarization and inhibition of firing in cells (Hannon & Hoyer, 
2008). What was previously termed the 5-HT1c receptor has been reclassified as the 5-HT2C 
receptor after it was found to be more closely related to the 5-HT2 family (D Hoyer et al., 1994). 
Depending on the brain regions, the 5-HT1A receptor can cause neuronal hyperpolarization by 
inhibition of adenylyl cyclase activity and/or the opening of potassium channels. In addition, the 
receptor autoradiography studies revealed that the density of 5-HT1ARs is higher in hippocampus, 
lateral septum, cortical areas and the mesencephalic raphe nuclei compared with the basal 
ganglia and cerebellum (Hannon & Hoyer, 2008; Pedigo, Yamamura, & Nelson, 1981). Moreover, 
in situ hybridization and immunocytochemical studies further demonstrate that 5-HT1ARs exist in 
cortical pyramidal neurons, pyramidal and granular neurons of the hippocampus. It has been 
found in the hippocampus, 5-HT1ARs are coupled to both effector systems while in the dorsal 
raphe nucleus, 5-HT1ARs are coupled only to the opening of potassium channels (Frazer & 
Hensler, 1999). 
The 5-HT1B and 5-HT1D receptor also inhibit adenylyl cyclase activity. The 5-HT1B 
receptor was originally thought to be rodent-specific, whereas 5-HT1D is limited to non-rodents, 
However, studies found high similarities in transduction features, function, and brain distribution 
between these two receptors (Daniel Hoyer & Middlemiss, 1989). Therefore, the rodent ‘5-HT1B’ 
and non-rodent ‘5-HT1D’ receptors are now thought to be species homologues. But, this opinion is 
questioned again because two genes encoding the human 5-HT1D receptor, 5-HT1Dα and 5-HT1Dβ 
have been discovered (D Hoyer et al., 1994). Further studies are needed to determine whether 
the 5-HT1B and 5-HT1D receptors are species homologs or distinct 5-HT receptor subtypes. 
in situ hybridization has localized the expression of 5-HT1E receptors. It has been found 
the 5-HT1E receptors mostly exist in the caudate putamen, parietal cortex and olfactory tubercle. 
The exact function of the 5-HT1E receptor in vivo is not clear due to the lack of selective agonists 
or antagonists. In addition, the homology with the 5-HT1D receptor of 5-HT1E receptor is 64%, 
which is higher than any other 5-HT1 receptor (D Hoyer et al., 1994). However, both the 5-HT1E 
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and 5-HT1F receptor inhibit adenylyl cyclase activity in vitro (Lucas & Hen, 1995). In addition, the 
5-HT1F receptor is 61% homologous with 5-HT1E receptors. The 5-HT1F receptor is widely 
distributed throughout the nervous system including in the cortex, hippocampus, and spinal cord 
(D Hoyer et al., 1994).  
The 5-HT2 receptor family includes the 5-HT2A, 5-HT2B and 5-HT2C receptors. They 
share 46-50% sequence identity and couple preferentially to Gq/11 to increase inositol 
phosphates and cytosolic Ca
2+
 to induce muscle contraction and neuron activation in the brain 
(Julius, Huang, Livelli, Axel, & Jessell, 1990). The 5-HT 2AR encoding gene HTR2A is highly 
expressed in the cerebral cortex (especially in laminae I and IV-Va), the olfactory bulb, and in the 
brain stem, but at only very low levels in the cerebellum, thalamic nuclei and hippocampus. It has 
been further identified that 5-HT2A receptors are expressed in pyramidal cells and interneurons in 
the neocortex (Hannon & Hoyer, 2008). In addition, HTR2A gene promoter polymorphisms are 
associated with the response to clozapine in schizophrenia patients (Arranz, Munro, & Owen, 
1998). The T102C polymorphism in HTR2A was found to be associated with schizophrenia in 
several populations (Lin et al., 2015; Sujitha et al., 2014). Moreover, mice lacking 5-HT2A 
receptors shows a paradoxical constitutive behavioral sensitization to amphetamine (Salomon et 
al., 2007), as well as changes in sleep pattern opposite to WT mice (Popa, Prenat, Gingrich, 
Escourrou, & Hamon, 2005). Those findings suggest that 5-HT2A receptors also play an important 
role in sleep-wakefulness regulation. Furthermore, it is found that MDL100907, a selective 5-HT2A 
receptor antagonist, does not impact short term memory (STM) but facilitates long term memory 
(LTM). However, the selective 5-HT1B receptor antagonist SB-224289 facilitated both STM and 
LTM (Meneses, 2007). These findings indicate that 5-HT mediates STM and LTM via binding to 
5-HT1B receptors, whereas other receptors are also involved in memory. 
In rat, the 5-HT2B mRNA is extensively detected in peripheral organs, but is not detected 
in brain using quantitative polymerase chain reaction (qPCR) (D Hoyer et al., 1994). In contrast, 
5-HT2B receptor immunoreactivity has been detected in rat brain but only restricted to a few brain 
regions such as cerebellum, dorsal hypothalamus and medial amygdala. Moreover, the cells 
expressing 5-HT2B receptor immunoreactivity are more like neurons but not astrocytic cells 
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(Bonhaus et al., 1995). Thus, further studies are needed to decipher the controversial of 5-HT2B 
receptor’s presence in the brain, especially that of the rat. In humans, 5-HT2B receptor mRNA has 
been found both in peripheral organs and in brain regions such as cerebellum, cerebral cortex (D 
Hoyer et al., 1994). It has been reported that 5-HT2B receptors on endothelial cells mediate vaso-
relaxation via nitrogen oxides (NO) release (Linder, Gaskell, Szasz, Thompson, & Watts, 2010). 
In addition, in human small intestine, 5-HT2B receptors mediate the longitudinal muscle 
contraction (Fitzgerald et al., 2000). Moreover, the deletion of 5-HT2B receptor in mice causes 
severe embryonic defects and is lethal. However, the overexpression this receptor in mice leads 
to severe cardiovascular disorder (Nebigil et al., 2003). 
Both the 5-HT2c receptor and mRNA expression are detected in the choroid plexus and 
limbic structures include hippocampus, amygdala and anterior olfactory of rodent (Daniel Hoyer, 
Waeber, Schoeffter, Palacios, & Dravid, 1989). In addition, the 5-HT2C receptor cys23ser 
polymorphism is found associated with vulnerability to affective disorders (Lerer et al., 2001). 
Furthermore, both typical and atypical antipsychotics have inverse agonist activity at the human 
5-HT2C receptors (Rauser, JE, HY, & BL, 2001). Another -759C/T polymorphism also affects the 
5-HT2C receptor-encoding gene HTR2C expression; the -759T containing promoter has a higher 
transcriptional activity than the more common -759C allele, which underlies the vulnerability to 
antipsychotic-induced weight gain in schizophrenia patients (Buckland et al., 2005). Moreover, 
the HTR2C-/- mouse is severely overweight because of abnormal food intake regulation and may 
also experience fatal seizures (Tecott et al., 1995).  
The 5-HT3 receptor family is LGICs that can induce the rapid depolarization of neurons 
by a transient current of cations (Na
+
, Ca
2+
 influx, K
+ 
efflux) (D Hoyer et al., 1994). Electron 
microscopy has identified that the native 5-HT3 receptor is a pentamer composed of 5 subunits 
surrounding a central channel (Boess, Beroukhim, & Martin, 1995). Using receptor radioligand 
binding assay, 5-HT3 receptor has been found highly distributed in at the dorsal vagal complex 
mediating the vomiting reflex (Hannon & Hoyer, 2008). In addition, it is found that 5-HT3 receptor- 
immunoreactive GABAergic interneurons in the rat telencephalon also contain cholecystokinin 
(CCK), which indicates serotonin may regulate GABA and CCK activity via binding to the 5-HT3 
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receptor (Morales & Bloom, 1997). Recently, other 5-HT3 receptor subtypes such as 5-HT3C, 5-
HT3D, 5-HT3E, have also been reported (Niesler, Frank, Kapeller, & Rappold, 2003). However, 
more information pertaining to their specific features has yet to be clarified. 
5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors include a group of serotonin receptors 
preferentially coupled to the Gs-proteins and mediate intracellular levels of adenylyl cyclase. The 
5-HT4 receptor is highly expressed in the nigrostriatal and mesolimbic systems, and is involved in 
learning and memory (Dumuis, Bouhelal, Sebben, Cory, & Bockaert, 1989). In addition, 5-HT4 
receptor KO mice exhibit abnormal feeding and locomotor behavior in response to stress and 
novelty, and hypersensitivity to seizures (Compan et al., 2004). The transduction pathways and 
the function of 5-HT5 receptors have not been well established. 5-HT5A receptor KO mice show 
increased exploratory activity in a novel environment, which suggests a putative role of 5-HT5A 
receptors in adaption under stress (Wesołowska, 2002). Rat and human 5-HT6 receptors are 
found in central nervous system regions such as striatum, hippocampus, and cortex, but not in 
peripheral tissues (Frazer & Hensler, 1999). It has been found that various antipsychotic and 
antidepressant drugs have a high affinity for the 5-HT6 receptor,, and the use of antagonists 
increase cholinergic neurotransmission and have positive effects on learning and memory 
(Hannon & Hoyer, 2008). 5-HT7 receptors have been identified in peripheral tissues, such human 
vascular smooth muscle cells, and in central nervous system tissues, such as suprachiasmatic 
nucleus, thalamic nuclei and cortical regions (Leung, Walsh, Pulido-Rios, & Eglen, 1996), which 
suggests this receptor may regulate sleep, circadian rhythmic activity and mood. It has been 
reported that 5-HT7 receptor KO mice exhibit reduced immobility in the forced swim test, 
suggesting an ‘antidepressant-like’ phenotype. Treatment of wildtype mice with a selective 5-HT7 
receptor antagonist did not decrease immobility unless tested in the dark (or active) cycle, which 
indicate a circadian influence on receptor function (Guscott et al., 2005). 
In summary, the 5-HT receptor subtypes are complex and involved in many biological 
functions. Given the diversity of symptoms in schizophrenia, it is difficult to identify a single gene 
which accounts for all types of abnormalities. A comprehensive examination of serotonergic 
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system in various developmental stages under wide range of environmental stimuli in 
schizophrenia patients will be helpful to find potential therapeutic targets. 
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